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1  Abbreviations 
 
3MeH3K27 tri-methyl-histone H3 Lys27  
AcH4 acetyl-histone H4  
AMI amitriptyline  
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid  
AVP arginine vasopressin  
BDNF brain-derived neurotrophic factor  
CBZ carbamazepine  
CER cerebellum  
CIT citalopram  
CREB cAMP response element-binding  
CTX cortex  
DEX dexamethasone  
DNMT DNA methyltransferase 
E1 exon 1 
EAAC1 excitatory amino acid carrier 1 
EAAT excitatory amino acid transporter  
EGF epidermal growth factor   
ETS E-twenty six  
GADD45α growth arrest and DNA-damage inducible 45α 
GFAP glial fibrillary acidic protein  
GLAST glutamate-aspartate transporter  
Gln glutamine 
GLT-1  glutamate transporter 1  
Glu glutamate 
HAT histone acetyltransferase  
HDAC histone deacetylase  
HDAC-I histone deacetylase inhibitor  
HDM histone demethylase  
HMT histone methyltransferase  
HPC hippocampus 
iGluR ionotropic glutamate receptor 
LINE-1 long interspersed nuclear element 1 
LTG lamotrigine  
LUMA luminometric methylation analysis  
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MBD methyl-CpG-binding domain 
MeCP methyl-CpG binding protein 
mGluR metabotropic glutamate receptor 
NGFI-A nerve growth factor induced clone A  
NMDA N-methyl-D-aspartate  
PAR paroxetine  
RNA pol RNA polymerase 
Sp1 specificity protein 1  
SUMO small ubiquitin-like modifier 
SUV39 3–9 suppressor of variegation  
TET1 ten-eleven translocation 1 
TF transcription factor 
TSA trichostatin A  
VEN venlafaxine  
VPA valproic acid
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2  Summary 
 
Epigenetic mechanisms confer stability of gene expression but are also subject of 
reprogramming by various stimuli including stress and psychoactive drugs. In this thesis, the 
epigenetic regulation of the rat glutamate transporter 1 (GLT-1) gene was analysed, focusing 
on the CpG island and the upstream CpG shore. In particular, I sought to decipher the 
contribution of chromatin modifications to differential GLT-1 response to the stress hormone 
dexamethasone (DEX) in cortical (CTX) and cerebellar (CER) astrocytes. In addition to DEX, 
epigenetic effects of mood stabilizers and antidepressants on GLT-1 including the histone 
deacetylase inhibitor (HDAC-I) valproic acid (VPA), carbamazepine, lamotrigine, amitriptyline 
(AMI), venlafaxine and citalopram were assessed. Genome-wide epigenetic effects of these 
drugs on primary astrocytes were also evaluated. Chromatin analysis demonstrated that 
repressive marks at the CpG shore region correlated with GLT-1 unresponsiveness to 
treatment with DEX in CER, whereas positive marks were associated with increased GLT-1 
transcription in CTX following treatment with DEX and HDAC-Is. Importantly, the CpG shore 
acted as a stress hormone- as well as HDAC-I-responsive enhancer element in a 
methylation-dependent fashion in reporter gene assays. The extent of epigenetic 
reprogramming at the GLT-1 promoter by DEX and HDAC-Is was more pronounced in CTX, 
where VPA induced marked DNA demethylation and histone H4 hyperacetylation of the CpG 
shore. Except for VPA, the GLT-1 gene was not a subject to epigenetic regulation by the 
other investigated psychoactive drugs and none of them affected GLT-1 transcription. 
However, VPA as well as AMI promoted genome-wide reversible DNA demethylation at 
CCpGG sites in CTX astrocytes, as measured by luminometric methylation analysis. In the 
case of VPA, global DNA demethylation was associated with histon H3/H4 hyperacetylation 
and 2MeH3K9 hypomethylation, as determined by Western Blot. VPA-associated 
demethylation at CCpGG sites occurred independently of DNA methyltransferase (DNMT) 
suppression. In the case of AMI, however, CCpGG demethylation was paralleled by a 
reduction of DNMT enzymatic activity. The results of this thesis support the notion that the 
epigenetic landscape of the CpG shore generates different GLT-1 transcriptional outcomes 
and can be modulated in particular by drugs with HDAC-I properties. Furthermore, the 
results indicate that VPA and AMI target different genes and interfere with distinct 
components of the processes leading to DNA demethylation. The data presented here 
extend our understanding of epigenetic regulation in neural cells and pave the way to 
identification and characterization of promising novel drug targets. 
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3  Introduction 
 
3.1. Cellular and molecular features of glutamate transporters 
 
3.1.1. Neuroregulatory functions of astrocytes  
Glutamatergic neurotransmission is crucial for brain functions such as cognition, memory 
and learning. Excitatory potentials are evoked by activation of several transmembrane 
glutamate receptors: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), 
N-methyl-D-aspartate (NMDA), kainate and metabotropic (group I-III) glutamate receptors. 
Glutamatergic firing must be rapidly terminated in order to prevent cytotoxicity and ensure 
optimal cell-to-cell communication. The key elements of glutamate clearance from the 
extracellular space are sodium-dependent excitatory amino acid transporters (EAAT), 
expressed mainly on astrocytes but also on neurons. The glutamate taken up by astrocytes 
is metabolised to glutamine and transported to neurons. This trafficking of glutamate and 
glutamine between astrocytes and neurons is commonly referred to as the 
glutamate-glutamine cycle (Fig. 1). Apart from the role in metabolism and glutamate 
clearance, astrocytes are integral components of the “tripartite glutamatergic synapse”. 
Neuron-astrocyte communication within these synapses relies on the expression of 
neurotransmitter receptors on astrocytes including dopamine and serotonin receptors (Brito 
et al., 2009; Carson et al., 1996). Active release of neurotransmitters from astrocytes has 
also been documented (Panatier et al., 2006; Perea and Araque, 2007). A growing body of 
data indicates that astroglial cells have the capacity to integrate neuronal inputs and 
modulate synaptic potentials on neighbouring neurons, concomitantly influencing 
behavioural responses (Halassa and Haydon, 2010).  
 
 
3.1.2. Types and localisation of glutamate transporters 
Glutamate uptake is mediated by a family of membranous transport proteins. High-affinity 
glutamate transporters were first identified in rodents and designated as glutamate-aspartate 
transporter (GLAST) (Storck et al., 1992), glutamate transporter 1 (GLT-1) (Pines et al., 
1992) and excitatory amino acid carrier 1 (EAAC1) (Kanai and Hediger, 1992). Identification 
of the human glutamate transporters EAAT1, EAAT2, EAAT3 corresponding to GLAST, 
GLT-1 and EAAC1 followed up (Arriza et al., 1994). Subsequently, two additional 
mammalian transporter subtypes were identified, EAAT4 (Fairman et al., 1995) and EAAT5 
(Arriza et al., 1997). Localization studies have shown that GLAST and GLT-1 are almost 
exclusively glial transporters (Fig. 2). They are also present in developing neurons (Plachez  
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et al., 2004; Wang et al., 1998), although there are still controversies concerning neuronal 
protein localisation in vivo (Berger et al., 2005; Holmseth et al., 2009). In contrast to GLAST 
and GLT-1, EAAT3 and EAAT4 are found predominantly in neurons, with EAAT3 being 
abundant throughout the central nervous system and EAAT4 unique to Purkinje cells of the 
cerebellum (Furuta et al., 1997a). Lastly, EAAT5 is a retinal glutamate transporter (Rauen et 
al., 2004). 
 
 
3.1.3. Role of GLT-1/EAAT2 in disease 
Astrocytic GLT-1/EAAT2 is a major molecular determinant of the glutamate removal from the 
synaptic cleft. Mice deficient in GLT-1 display spontaneous lethal seizures and are highly 
susceptible to injury-induced edema formation (Tanaka et al., 1997). A number of 
neurological disorders are linked to glutamate transporter dysfunction such as amyloid 
lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, stroke and epilepsy, which is 
also supported by animal models based on abnormal glutamate neurotransmission 
(Maragakis and Rothstein, 2004). Moreover, growing evidence supports the role of disrupted 
glutamate homeostasis in the pathophysiology of clinical depression. Individuals with mood 
disorders show elevated glutamate levels in cortex (CTX) in nuclear magnetic resonance 
 
 
Figure 1. The glutamate-glutamine cycle. Glutamate (Glu) released from presynaptic vesicles is 
taken up by Glu transporters present on neurons and astrocytes. In astrocytes, Glu is converted into 
glutamine (Gln) in an ATP-dependent process. Gln is then released into the extracellular cavity by 
means of Gln transporters, taken up by neurons and converted into Glu by the mitochondrial enzyme 
phosphate-activated glutaminase. In neuronal presynaptical terminals, Glu is packaged into synaptic 
vesicles and released on demand by exocytosis. 
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spectroscopy studies (Sanacora et al., 2004; Yildiz-Yesiloglu and Ankerst, 2006) as well as 
aberrant expression of genes associated with regulation of glutamate clearance and 
metabolism (Altar et al., 2009). Accordingly, certain areas of the cerebral CTX of patients 
who suffered from major depressive disorder demonstrate significant down-regulation of 
EAAT2 levels (Choudary et al., 2005). Furthermore, ketamine and other NMDA receptor 
antagonists produce fast-acting behavioural antidepressant-like effects in mouse models 
(Autry et al., 2011). Accumulation of extracellular glutamate also potentially causes cytotoxic 
damage to neurons and glia (Choi, 1988). Significantly reduced numbers of neuroglia in 
patients with major depression have been reported (Rajkowska, 2000), evidencing a role of 
high glutamate levels in depression. Thus, uncovering the mechanisms of GLT-1/EAAT2 
gene regulation is critical not only for understanding fundamental cellular processes, but also 
in finding a new therapeutic approach that aims to promoting glutamate transport in 
astrocytes. 
 
 
Figure 2. Mechanism of excitatory neurotransmission in the mammalian central nervous 
system and distribution of excitatory amino acid transporters (EAAT). L-glutamate (Glu) is 
synthesized in presynaptic terminals. Following release, Glu acts via ionotropic glutamate receptors 
(iGluR) AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and NMDA 
(N-methyl-D-aspartate) and metabotropic glutamate receptors (mGluR). The synaptic effects of Glu 
are terminated by its uptake mediated by several EAATs, primarily GLT-1/EAAT2, and to a lesser 
extent GLAST/EAAT1. EAAT1 and EAAT2 are predominantly expressed in astrocytes. In astrocytes, 
Glu is transformed to glutamine (Gln) and shuttled back to presynaptic terminals via glutamine 
transporters (GlnT). Neuronal EAATs, including EAAT3/EAAC1 (expressed primarily in the forebrain) 
and EAAT4 (expressed predominantly in Purkinje cells), have a role in synaptic plasticity. Transport of 
Glu via EAATs is coupled with the inward co-transport of three Na
+ 
and one H
+
 ion and the export of 
one K
+
 ion. 
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3.1.4. Regulation of astrocytic GLT-1/EAAT2  
Primary cultures of neonatal astrocytes constitute a useful model for elucidation of 
GLT1/EAAT2 gene regulation. Using primary astrocytes, numerous factors were found to 
enhance GLT-1/EAAT2 expression including growth factors (Figiel et al., 2003; 
Rodriguez-Kern et al., 2003), cAMP analogues (Schlag et al., 1998), beta-lactam antibiotics 
(Rothstein et al., 2005), steroids (Pawlak et al., 2005; Tian et al., 2007; Zschocke et al., 
2005), histone deacetylase inhibitors (HDAC-Is) (Allritz et al., 2009), insulin (Ji et al., 2011), 
dopamine (Brito et al., 2009) and many more. Some of these effects were also reported in 
vivo, in particular the regulation by corticosteroids (Autry et al., 2006; Reagan et al., 2004) 
and HDAC-Is (Hassel et al., 2001).  
Molecular mechanisms of GLT-1/EAAT2 regulation have been partially addressed, 
especially factors that mediate the effects of epidermal growth factor (EGF), tumour necrosis 
factor α and cAMP analogues (Li et al., 2006; Sitcheran et al., 2005; Zelenaia et al., 2000). 
These studies suggest an involvement of phosphatidylinositol 3-kinase- and nuclear 
transcription factor-kappa B-dependent pathways. Another study described a mechanism of 
EAAT2 regulation based on translational control through cis-regulatory elements in the 
5’-UTR of the EAAT2 mRNA (Tian et al., 2007). Moreover, the role of the 3’-UTR and 
non-coding RNA in the control of GLT-1/EAAT2 has recently been suggested (Bette et al., 
2011). 
Furthermore, there is evidence for the involvement of brain-region specific factors which 
determine GLT-1 regulation. Pharmacological stimulation of primary astrocytes results in 
increased levels of GLT-1 depending on the brain region investigated. For instance, GLT-1 
expression is elevated by pituitary adenylate cyclase-activating polypeptide, tumour growth 
factor α and EGF in astrocytes from striatum, whereas these factors fail to increase GLT-1 
levels in astrocytes from cerebellum (CER), mesencephalon and spinal cord (Schluter et al., 
2002). Corticosteroids increase GLT-1 transcription in CTX but not in CER and 
mesencephalon astroglia (Zschocke et al., 2005). This differential inducibility of GLT-1 in 
astrocytes from diverse brain regions may have its origin in regional segregation of 
glutamate transporter subtype expression during pre- and postnatal brain development 
(Furuta et al., 1997b). In the adult rat brain, GLT-1 transporter subtype is more abundant in 
CTX than GLAST subtype, the latter being the predominant glutamate transporter in CER 
astrocytes. Local specialisation of astrocytes during development is also reflected by 
regionally distinct connexin 43 inducibility (Reuss et al., 1998; Reuss et al., 2000) as well as 
distinct gene expression patterns in astrocytes from CTX, CER and brainstem (Yeh et al., 
2009).  
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Epigenetic control is a fundamental regulatory mechanism that underpins the establishment 
of brain-area specific gene activity and reactivity and was proposed to play a role in 
differential response to the stress hormone dexamethasone (DEX) between CTX and CER 
astrocytes (Zschocke et al., 2005). Follow-up studies supported this idea by documenting a 
significant epigenetic component in GLT-1/EAAT2 regulation in glioma cell lines as well as in 
neonatal astrocytes (Yang et al., 2010; Zschocke et al., 2007). Thus, these studies 
established an important basis for further investigations of epigenetic mechanisms in 
regulating GLT-1/ EAAT2.  
 
 
3.2. Epigenetics 
 
 
3.2.1. Terminology of epigenetics 
The term “epigenetics” was historically used to describe heritable phenotypic changes that 
do not entail a change in DNA sequence. Cellular differentiation and specialisation represent 
an example where epigenetic mechanisms come to play through selective activation and 
silencing of genes across the genome. This is why, in a more narrow sense, epigenetics is 
used to describe chromatin altering events which lead to changes in gene expression.  
 
 
3.2.2. Histone modifications and gene regulation 
Epigenetic processes use chromatin as a principal substrate. A major building block of the 
chromatin, called nucleosome, is formed by a 147 bp-long DNA stretch wrapped around one 
histone octamer comprised of two copies each of histone H2A, H2B, H3 and H4 (Fig. 3). 
There are other minor histone variants which are involved in the control of chromatin 
accessibility and specific functions such as DNA repair (Sarma and Reinberg, 2005). 
Numerous chemical groups can be enzymatically attached to N- and C-termini of histones 
including acetyl-, methyl-, phospho-, ubiquitin-, ADP-ribosyl-, and small ubiquitin-like modifier 
groups. Histone modifications do not occur in isolation but appear as combinations of marks 
which led to the proposal of the existence of a “histone code” (Jenuwein and Allis, 2001). 
The most investigated modifications are histone acetylation and histone methylation, 
especially of lysine (K) residues (Fig. 4). Acetylation of histones is catalysed by histone 
acetyltransferase (HAT) and numerous transcription factors and coregulators have been 
identified to possess intrinsic HAT activity. Histone acetylation can be reversed by histone 
deacetylase (HDAC) resulting in a dynamic transition of gene activity (Eberharter and 
Becker, 2002). Similarly, histone methyltransferases (HMT) and specific histone 
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demethylases (HDM) catalyze the transfer and removal of methyl-groups on histone 
residues, respectively (Mosammaparast and Shi, 2010; Nimura et al., 2010). 
Post-translational modifications of histones influence folding and the functional state of the 
chromatin fiber ultimately affecting gene transcription (Berger, 2001; Grunstein, 1997). 
Histone acetylation is generally associated with gene activation (Durrin et al., 1991; 
Pokholok et al., 2005), whereas histone methylation affects gene activity both positively and 
negatively depending on the number and location of attached methyl-groups (Lachner and 
Jenuwein, 2002; Spencer and Davie, 1999). 
 
 
3.2.3. DNA methylation and gene silencing 
Another global mechanism which regulates the extent of chromatin accessibility is DNA 
methylation. DNA methylation is catalysed by DNA methyltransferases (DNMT) and in 
mammals, it is almost exclusively confined to CpG dinucleotides. Methylation of cytosines is 
carried out by three types of DNMT: DNMT1, DNMT3a and DNMT3b. The DNMT1 protein 
function is tightly linked to DNA replication and maintenance of the methylation pattern 
(Leonhardt et al., 1992), whereas DNMT3a and DNMT3b function as de novo 
methyltransferases (Okano et al., 1999), supported by the activity of the ancillary subtype 
DNMT3L (Bourc'his and Bestor, 2004; Jurkowska et al., 2011). However, there is also 
evidence that DNMT3a and DNMT3b are required for the maintenance of certain methylation 
patterns (Chen et al., 2003; Liang et al., 2002; Jair et al., 2006), and that DNMT1 could 
participate in de novo methylation as well (Jair et al., 2006).  
Genomic stretches with a high frequency of the CpG dinucleotides, so called CpG islands, 
are generally found in gene promoter regions (Bird, 1986). CpG islands are typically 
maintained in an unmethylated state, whereas the rest of the genome is highly methylated. 
 
Figure 3. Schematic presentation of a nucleosome. In a nucleosome, the DNA is wrapped around 
an octamer of histones 1.65 times in a left-handed superhelix. The histone octamer consists of two 
copies of each core histone (H2A, H2B, H3 and H4). 
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There are also examples of CpG islands that become methylated during normal 
development or tumorigenesis, leading to stable silencing of the associated promoter 
(Baylin, 2002; Mohn et al., 2008; Stein et al., 1982). However, expression of the gene is not 
necessarily fully determined by the methylation status of its promoter CpG island (Weber et 
al., 2007). Genomic regions in the vicinity of CpG islands (termed as CpG island shores) 
also regulate gene activity in a methylation-dependent manner and may act as cell 
type-specific enhancers (Irizarry et al., 2009; Schmidl et al., 2009). 
In general, DNA methylation prevents binding of transcription factors  (Campanero et al., 
2000; Iguchiariga and Schaffner, 1989) or recruits methyl-CpG binding (MeCP) proteins 
which together with numerous chromatin factors establish a repressive chromatin state 
(Fuks et al., 2003; Jones et al., 1998; Nan et al., 1998) (Fig. 5). However, a growing number 
of studies suggest that establishment of DNA methylation profiles and gene silencing during 
early development might be initiated through histone modifications, which serve as primary 
epigenetic marks (Lock et al., 1987; Ooi et al., 2007; Tamaru and Selker, 2001). For 
example, DNMT1 targets transcriptionally repressive chromatin through association with 
HDAC1 and HDAC2 in vivo, as well as with the HMT suppressor of variegation 3–9 (SUV39) 
(Fuks et al., 2000; Rountree et al., 2000). Regardless of the hierarchical order of events, a 
cross-talk between DNA methylation and histone modifications is supported by both 
circumstantial and direct evidence (D'Alessio and Szyf, 2006). 
 
 
 
Figure 4. Common covalent modifications of histone H3. Schematic representation of the 
post-translational modifications of the N-terminal domain of H3 at some lysine (K) and arginine (R) 
residues. Acetylation is catalysed by histone acetyltransferases (HAT) and reversed by histone 
deacetylases (HDAC), whereas lysine methylation (linked to either transcriptional activation or 
repression) is catalysed by histone methyltransferases (HMT) and reversed by histone demethylases 
(HDM).  
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Figure 5. Inhibition of gene activation by CpG methylation.  In normal cells, CpG islands are 
unmethylated and often located in or near the transcription start sites of genes in the proximity of exon 
1 (E1). Unmethylated CpGs permit binding of RNA polymerase (RNA pol) and other transcription 
factors (TF) and thereby enable the initiation of productive transcription. Methylation of CpGs directly 
hinders the binding of transcriptional machinery. Alternatively, DNA methylation provides recognition 
signals for the methyl-CpG-binding domain (MBD) protein components of a histone deacetylase 
complex (HDAC). The HDAC modifies the chromatin by deacetylating histones (depicted as yellow 
stars) in the region of the CpG island and hence indirectly inactivates the gene. 
 
 
3.2.4. Dynamics of DNA methylation 
In recent years, a number of studies link an active, replication-independent DNA 
demethylation with gene activation (Barreto et al., 2007; Kim et al., 2009; Milutinovic et al., 
2007). In plants, mechanisms of active DNA demethylation are better understood, while the 
evidence for mammalian demethylases still remains contradictory. It seems that in 
mammals, depending on the context, this process may be achieved by multiple 
mechanisms. The initial studies on active DNA demethylation reported an involvement of an 
RNA-dependent mechanism (Jost, 1993; Weiss et al., 1996), which was questioned later on 
(Swisher et al., 1998). Active DNA demethylation mediated by methyl-CpG-binding proteins 
has been demonstrated at promoters of the brain-derived neurotrophic factor (BDNF) and 
cytochrome p450 27B1 gene (Kim et al., 2009; Martinowich et al., 2003). In the latter study, 
a DNA repair-dependent mechanism was suggested, which is supported by data from 
several studies that highlight the role of growth arrest and DNA-damage inducible 45α 
(GADD45α) protein (Barreto et al., 2007; Schmitz et al., 2009). More recently, the base 
excision repair pathway was suggested to initiate an oxidative deamination mechanism to 
actively demethylate DNA (Guo et al., 2011). This process is mediated by ten-eleven 
translocation 1 (TET1) enzyme and entails formation of 5-hydroxymethylcytosine. 
Furthermore, there is also a bidirectional cross-talk between DNA demethylation and histone 
hyperacetylation (Cervoni and Szyf, 2001; D'Alessio et al., 2007; Jackson et al., 2004; 
Milutinovic et al., 2007). Although details of the demethylation mechanism remain unknown, 
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many studies evidence that established DNA methylation patterns in non-dividing cells can 
be erased. Therefore, DNA methylation is a much more dynamic process than previously 
thought, and pharmacological agents with DNA demethylation properties could be used for 
reprogramming of not only transformed, but also differentiated cell populations. 
 
 
3.2.5. Epigenetic basis of stress-induced behavioural changes 
Epigenetic processes are susceptible to changes caused by endogenous as well as by 
external cues (Fagiolini et al., 2009; Meaney, 2010). Environmental influences are 
established risk factors for many diseases including psychiatric illnesses. Thus, it is 
suggested that there may be an epigenetic route to the consolidation of maladaptive 
behaviour. Among the environmental factors, stress plays a prominent role in the aetiology 
of psychiatric disorders. Experimental evidence from studies on animals shows how stress 
modifies behaviour based on epigenetic mechanisms. In one of the pioneering studies in this 
field, Weaver et al. demonstrated that early life stress in rats elicits long-lasting changes in 
the sensitivity of the hypothalamic-pituitary-adrenal axis which is associated with altered 
histone acetylation, DNA hypermethylation and nerve growth factor induced clone A 
(NGFI-A) transcription factor binding to the promoter of the glucocorticoid receptor gene 
(Weaver et al., 2004). Interestingly, central infusion of a histone deacetylase inhibitor reverts 
epigenetic changes and aberrant stress response. Adverse effects of early life stress are 
also associated with changes in arginine vasopressin (AVP) expression levels in rodent 
neurons (Murgatroyd et al., 2009). The AVP gene is epigenetically programmed by stress 
through DNA hypomethylation of the distal promoter sequence which reduces MeCP2 
binding. Further support for the possible role of chromatin modifications in development 
and/or maintenance of certain psychopathological phenotypes was provided by studies 
reporting that systemic administration of the HDAC-Is sodium butyrate and suberoylanilide 
hydroxamic acid elicits antidepressant-like effects in animal models of depression 
(Schroeder et al., 2007; Uchida et al., 2011). Moreover, systemic or intra-hippocampal 
administration of DNMT inhibitors in rats induces dose-dependent DNA hypomethylation, 
increased BDNF levels and alleviation of depression-like symptoms in animals (Sales et al., 
2011).  
 
 
3.2.6. Epigenetic mechanism of action of psychoactive drugs 
A growing number of studies report that pharmacological effects of certain psychoactive 
drugs could be epigenetically mediated as well. Chronic treatment with imipramine reverses 
stress-induced repression of the BDNF gene in the hippocampus (HPC) (Tsankova et al., 
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2006). These changes are accompanied by an increase in the level of active histone marks 
acetyl-histone H3 and methyl-histone H3 Lys4 at BDNF promoters and reversal of the 
depression-like phenotype. Antipsychotic effects of clozapine are ascribed to DNA 
hypomethylation at the glutamic acid decarboxylase 67 promoter in the CTX and striatum 
(Dong et al., 2008). Moreover, chronic administration of haloperidol slightly reduces the 
content of methyl-cytosines in the brain (Shimabukuro et al., 2009).  
Valproic acid (VPA) has been used in the treatment of epilepsy and bipolar disorder. In 
addition to its known classical actions which include increase of GABAergic activity and 
negative regulation of voltage gated Na+ channels (Monti et al., 2009), this drug inhibits 
HDACs (Gottlicher et al., 2001; Phiel et al., 2001). It has been proposed that therapeutic 
effects of VPA are partially brought about by reversal of chromatin marks at specific gene 
targets (Chen et al., 2002; Dong et al., 2008). Moreover, VPA treatment induces widespread 
epigenetic reprogramming by altering DNA methylation patterns (Milutinovic et al., 2007). 
Furthermore, chronic treatment of rats with VPA leads to a dose-dependent increase in the 
level of glutamate transporters GLT-1 and GLAST in the HPC and concomitant increase in 
glutamate uptake (Hassel et al., 2001). Trichostatin A (TSA), another HDAC-I with broad 
specificity, also elevates GLT-1 expression in neonatal astrocytes from different brain 
regions (Allritz et al., 2009). The DNMT inhibitor 5-aza-2'-deoxycytidine, alone or in 
combination with TSA, also activates GLT-1/EAAT2 (Zschocke et al., 2007), raising the 
exciting possibility of gene reprogramming by DNA demethylation. Together, these studies 
allude the possibility that epigenetic drugs induce local alterations of chromatin marks also at 
the GLT-1 promoter and thereby elevate GLT-1 transcription, but direct evidence is still 
missing. 
 
 
3.3. Aims of the thesis 
One of the aims of this thesis was to investigate in detail the epigenetic features of the 
GLT-1 gene promoter in rat primary CTX and CER astrocytes, as well as their susceptibility 
to alterations upon pharmacological challenge. CTX and CER astrocytes were chosen, 
because they exhibit differential responsivity to the stress hormone DEX, i.e. DEX evokes 
up-regulation of GLT-1 transcription in the CTX, but not in the CER (Zschocke et al., 2005). 
The epigenetic marks to be investigated were acetylated H4, several variants of methylated 
H3, and level of DNA methylation. Two regions of the GLT-1 promoter were assessed: the 
CpG island and the CpG island shore located 1.7-1.9 kb upstream of the transcription start 
site. DEX as well as the HDAC-Is TSA and VPA were used to study GLT-1 transcriptional 
responses mediated by stress hormone and epigenetic-modifying drugs, respectively. The 
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goal was to identify GLT-1 promoter element(s) which confer brain-region specific response 
to stress hormone in an epigenetic fashion.   
GLT-1 is also a target of psychoactive drugs other than VPA (Melone et al., 2001; Schneider 
et al., 1998; Tai et al., 2008). Thus, the further aim was to investigate whether certain 
antidepressants and mood stabilisers could modify promoter chromatin marks to interfere 
with GLT-1 transcription. In order to narrow the analysis, global chromatin modifications 
exerted by psychoactive drugs in astrocytes were first investigated. Detection of large-scale 
changes allows identification of drugs with pronounced chromatin modifying actions as a 
basis for more detailed investigation. Some frequently prescribed antidepressants including 
amitriptyline (AMI), venlafaxine (VEN), citalopram (CIT) and the mood stabilisers VPA, 
carbamazepine (CBZ) and lamotrigine (LTG) were chosen to evaluate possible epigenetic 
changes. To gain first insight into molecular processes tentatively involved in epigenomic 
alterations induced by psychoactive drugs, DNMT as well as DNA repair protein GADD45α 
expression were to be evaluated. 
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4  Results 
 
In this section, the results of this cumulative thesis are shortly summarised. They are 
presented in their full length in the articles included in the Appendix. Here, the publication 
“Valproate and amitriptyline exert common and divergent influences on global and gene 
promoter-specific chromatin modifications in rat primary astrocytes” is designated as PI and 
the publication “The CpG island shore of the GLT-1 gene acts as a methylation-sensitive 
enhancer” as PII. 
An examination of GLT-1 transcriptional activity under basal conditions as well as after DEX, 
VPA and TSA treatment in CTX and CER astrocytes was undertaken. As shown in Fig. 1A of 
PII, quantitative real-time analysis revealed no significant differences in GLT-1 mRNA levels 
between CTX and CER astrocytes under basal conditions. DEX treatment elevated GLT-1 
transcription in CTX, but not in CER astrocytes (PII, Fig. 1B). Treatment with VPA/TSA 
induced an increase of GLT-1 mRNA levels in CTX astrocytes (PI, Fig. 4A and B), 
contrasting their inhibitory effect in CER (PII, Fig. 1C; TSA data not shown).  
Next, a comparative analysis of active and repressive chromatin marks at the GLT-1 
promoter between CTX and CER astrocytes under basal conditions was performed. Two 
regions of the GLT-1 promoter were assessed: the CpG island and the upstream CpG shore. 
At both investigated regions, chromatin immunoprecipitation analysis revealed that the level 
of active acetyl-histone H4 (AcH4) mark was higher in CTX than in CER astrocytes 
(PII, Fig. 2A). In contrast, the level of the repressive tri-methyl-histone H3 Lys27 
(3MeH3K27) mark was higher in CER than in CTX astrocytes (PII, Fig. 2B).  
The analysis of the histone modifications at the GLT-1 promoter was complemented with 
examination of DNA methylation levels by using bisulfite sequencing. It was found that the 
CpG island in untreated astrocytes from both brain regions was unmethylated (not shown). 
However, at the CpG shore, CpGs were more methylated in CER than in CTX astrocytes 
(PII, Fig. 3B). Thus, a higher level of repressive marks and H4 hypoacetylation at the CpG 
shore region in CER astrocytes correlated with GLT-1 unresponsiveness to the stress 
hormone DEX.  
Furthermore, changes of chromatin marks at the GLT-1 promoter in primary astrocytes upon 
pharmacological stimulation with DEX, VPA and TSA were also elucidated. The results 
demonstrated that GLT-1 transcriptional response to DEX treatment notably correlated with 
increased AcH4 levels at the GLT-1 promoter in CTX astrocytes (PII, Fig. 2C). 
VPA/TSA-induced up-regulation of the GLT-1 transcription in CTX astrocytes was 
accompanied by DNA demethylation (PI, Fig. 3B) and H4 hyperacetylation (PI, Fig. 3C) of 
the CpG shore region. Surprisingly, the repression of GLT-1 transcription induced by VPA 
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treatment was also associated with increased AcH4 levels at the GLT-1 promoter in CER 
astrocytes (PII, Fig. 2E). For the first time, it could be demonstrated that changes of GLT-1 
transcription upon treatment with stress hormone and HDAC-Is are accompanied by 
alterations in chromatin marks at the gene promoter region.  
The transcriptional activity and pharmacological regulation of the GLT-1 promoter sequence 
was also tested in gene reporter assays. It was demonstrated that DEX and HDAC-Is 
stimulated the activity of the ectopic promoter in both CTX and CER astrocytes (PII, Fig. 4A 
and B; TSA data not shown), suggesting that CER cells provide the trans-acting factors 
necessary for GLT-1 activation. In an attempt to elucidate the contribution of methylation to 
the observed differences in gene expression, it was found that methylation of the whole 
promoter notably reduced GLT-1 promoter responsiveness to DEX and HDAC-Is (PII, 
Fig. 5A; TSA data not shown). In experiments specifically addressing the role of methylation 
at the CpG shore sequence on the GLT-1 promoter activity, it was shown that this region 
exhibited methylation-dependent enhancer function (PII, Fig. 5B and Fig. 6) 
Epigenetic changes induced by VPA, indicated by H4 hyperacetylation and DNA 
demethylation, were found locally at GLT-1 gene locus but this drug is also known for its 
genome-wide effects. Thus, it was important to investigate whether VPA and also other 
mood stabilizers like CBZ and LTG as well as the antidepressants AMI, VEN and CIT induce 
global epigenetic changes in rat primary CTX and HPC astrocytes. In addition, epigenetic 
effects of psychoactive drugs on GLT-1 transcription were assessed as well.  
Among the investigated mood stabilisers, only VPA evoked global changes in chromatin 
marks, including histone H3/H4 hyperacetylation (PI, Fig. 1) and 2MeH3K9 hypomethylation 
(PI, Fig. 6A and B) as well as DNA demethylation (PI, Table 2) in CTX and HPC astrocytes, 
as determined by Western blot and luminometric methylation analysis (LUMA), respectively. 
In the same cell types, TSA induced similar changes in global histone H3/H4 acetylation 
(PI, Fig. 1) and DNA methylation levels (PI, Table 2). Thus, the effects of VPA and TSA on 
the global histone acetylation and DNA methylation resembled the effects of these drugs at 
the GLT-1 locus in CTX astrocytes.  
In order to gain some insights into molecular mechanisms of DNA demethylation, two key 
factors responsible for propagation, maintenance or de novo establishment of DNA 
methylation patterns, DNMT1 and GADD45α were evaluated. The results showed that 
VPA-associated demethylation at CCpGG sites occurred under unchanged DNMT 
enzymatic activity (PI, Fig. 5C; contributed by Nicole Zimmermann) or its protein levels 
(PI, Fig. 5A). Also, DNA demethylation induced by VPA was not associated with global 
changes in the level of the DNA repair protein GADD45α (PI, Fig. 5A). Since LUMA 
exclusively monitors the methylation status at CCpGG sites, the level of methylation at all 
CpG sites was also determined by capillary electrophoresis analysis (contributed by Dr. 
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Francesca Tuorto, German Cancer Research Centre, Heidelberg). In addition, bisulfite 
sequencing-based measurement of the level of CpG methylation at long interspersed 
nuclear elements (LINE-1) sites was performed. Neither the level of total cytosine 
methylation (PI, Supplementary Table 1) nor the level of CpG methylation at LINE-1 sites 
(PI, Supplementary Fig. S3) was altered by VPA exposure. In addition, flow cytometry-based 
analysis of the percentage of dividing cells revealed that a very low percentage of the 
untreated astrocytes was in the S-phase of the cell cycle and that VPA reduced this number 
even further, suggesting an involvement of an active DNA demethylation process at CCpGG 
sites (PI, Supplementary Fig. S2).  
Investigation of the impact of antidepressants on global epigenetic modifications in primary 
astrocytes revealed that the tricyclic antidepressant AMI induced slight global cytosine 
demethylation (PI, Table 2). The changes of methylation at CCpGG sites were paralleled by 
a reduction of DNMT enzymatic activity (PI, Fig. 5C; contributed by Nicole Zimmermann), but 
not by a decrease of DNMT protein levels (PI, Fig. 5B). At the global level, the histone 
acetylation and methylation status remained unchanged after AMI treatment in CTX and 
HPC astrocytes (PI, Fig. 1 and Fig. 6). This investigation showed that AMI as well as the 
mood stabilizer LTG, in contrast to VPA and TSA, fail to stimulate EAAT2 (a human homolog 
of the GLT-1 promoter) transcriptional activity (PI, Fig. 4C) and induce GLT-1 promoter DNA 
demethylation (PI, Fig. 3B). 
Collectively this thesis emphasises the importance of the epigenetic settings at the CpG 
shore of GLT-1, which produces different transcriptional outcomes and drug responsiveness. 
Further, the psychoactive drugs VPA and AMI both change epigenetic parameters leading to 
DNA demethylation, but they use different pathways and target different genes. 
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5  Discussion 
 
The thorough examination of the epigenetic mechanisms controlling GLT-1 transcription, 
including their pharmacological modulation through stress hormone, HDAC-Is and 
psychoactive drugs, presents the following major contributions: 1. Histone modifications and 
DNA methylation are relevant in establishing control of GLT-1 transcription in both CTX and 
CER astrocytes and possibly account for their differential responsiveness to DEX and 
HDAC-Is. 2. The CpG island shore of the GLT-1 promoter acts as a stress hormone- as well 
as HDAC-I-responsive enhancer element in a methylation-dependent fashion. 3. While both 
VPA and AMI promote genome-wide reversible DNA demethylation at CCpGG sites, 
probably by distinct mechanisms, only VPA targeted the GLT-1 gene. 
It is generally accepted that epigenetic mechanisms regulate astrocytic differentiation during 
neural cell type specification in a temporally- and spatially-controlled manner (Hirabayashi 
and Gotoh, 2010). Dysregulation of these developmental programs by VPA or TSA 
treatment has marked effects on global histone acetylation and progenitor cell differentiation 
both in vivo and in vitro (Asano et al., 2009; Shen et al., 2005). Nevertheless, on the level of 
individual genes, only few examples that accompany astrocytic differentiation are 
characterised. For instance, phenotypic specialisation of astroglial cells is associated with 
extensive alterations of chromatin at glial fibrillary acidic protein (GFAP) and S100b gene loci 
in neural precursors (Hatada et al., 2008; Song and Ghosh, 2004; Takizawa et al., 2001). In 
this study, the CpG island of the GLT-1 was found to be unmethylated in neonatal CTX and 
CER astrocytes. When the CpG island of the human GLT-1 analogue EAAT2 is 
hypermethylated the transcription is silenced in vivo and in vitro (Zschocke et al., 2007). 
Conversely, the EAAT2 promoter is largely unmethylated in normal human CTX tissue and 
the protein is expressed. Accordingly, in this study, it was found that GLT-1 gene is 
transcribed under basal conditions at the same level in CTX and CER astrocytes. In 
untransformed cells, CpG islands of housekeeping and most of the tissue-specific genes 
generally remain unmethylated. The presence of specificity protein 1 (Sp1) binding sites at 
the GLT-1 promoter (Allritz et al., 2010), which seem to inhibit de novo methylation during 
development (Brandeis et al., 1994), may confer protection against DNA methylation. 
Moreover, within the CpG island of GLT-1, the active AcH4 mark was higher in CTX, 
whereas the repressive 3MeH3K27 mark was higher in CER astrocytes. Nevertheless, it 
appears that unmethylated CpGs are strong signals for binding of the transcription 
machinery in both cell types, irrespective of histone modifications. A few studies show that 
active histone marks can be present at methylated CpG islands of transcriptionally active 
promoters (Brinkman et al., 2007; Tshuikina et al., 2008). Thus, signals from DNA 
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methylation and histone modifications seem not always concordant. At some CpG islands, 
histone modifications govern transcriptional activity, while DNA methylation dominates at 
others. However, it is also possible that DNA methylation interferes with repressor binding at 
promoters associated with active histone marks.  
Analysing epigenetic modifications at the shore of the GLT-1 promoter, methylation of 
several neighbouring CpGs was significantly higher in CER than in CTX astrocytes. 
Furthermore, the experiments demonstrated that this GLT-1 promoter region exhibits 
prominent enhancer function after DEX/HDAC-I stimulation, suggesting existence of positive 
element(s) in this region. In silico analysis revealed numerous putative binding sites for 
transcription factors, of which some have been shown to regulate DEX-mediated response 
including cAMP response element-binding (CREB) protein and E-twenty six (ETS) (Espinas 
et al., 1994; van der Laan et al., 2009). Moreover, in vitro methylation had an inhibitory effect 
on transcriptional enhancement by DEX. The data are supporting the hypothesis that brain 
region-specific GLT-1 transcription in response to stress hormone is controlled by an 
enhancer element in a methylation-dependent manner. Recently, it was shown that DNA 
methylation of distal promoter sequences determines cell or tissue type-specific gene 
expression in untransformed cells and that these regions act as enhancer elements (Schmidl 
et al., 2009). In epigenetically induced pluripotent stem cells, differentially methylated 
regions occur more frequently at CpG island shores than at CpG islands, and these sites are 
tightly linked to genes involved in developmental and regulatory processes (Doi et al., 2009). 
These studies together with results reported here provide compelling evidence of the 
importance of CpG island shores in establishment of specific expression patterns and cell 
phenotypes. 
In addition to DNA methylation, histone modifications at distal enhancer elements are also 
highly correlated with cell type-specific patterns of gene expression (Heintzman et al., 2009). 
In this thesis, it was found that DNA of the GLT-1 shore region was not only hypomethylated 
but also accumulated higher level of hyperacetylated H4 in CTX, as opposed to CER 
astrocytes.  It is likely that such combination of chromatin marks in CTX cells conditions a 
permissive chromatin structure and increased GLT-1 transcription in response to DEX or 
HDAC-Is. In CER, however, the same region accumulated slightly higher amounts of 
3MeH3K27 while AcH4 was underrepresented. The H3K27 mark is thought to be set by 
DNA methylation (Erhardt et al., 2003; Mendenhall et al., 2010; Vire et al., 2006) and 
contributes to additional stabilisation of the repressive state. Thus, repressive chromatin at 
this region could antagonize or even decrease GLT-1 transcription in response to DEX and 
HDAC-I treatment, respectively. In a study by Bapat et al., it was reported that genes in 
CP70 cells possessing 3MeH3K27 enrichment at promoters are transcriptionally 
down-regulated after transition to different culture conditions (Bapat et al., 2010). Since 
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HDAC-Is exert marked stimulatory effect on ectopic GLT-1 promoter constructs, this 
supports the role of high order chromatin structure in GLT-1 transcriptional repression. 
However, it can not be excluded that HDAC-I-induced repression of the GLT-1 in CER 
astrocytes could be also mediated by some cell type-specific trans-acting factors.  
Chromatin is an integral component of mechanisms for transcriptional control but it is also 
susceptible to epigenetic reprogramming. Early-life stress elicits a reduction of DNA 
methylation at the AVP enhancer in hypothalamus under elevated corticosterone secretion 
(Murgatroyd et al., 2009). Also, chronic corticosterone exposure is accompanied by subtle 
alterations in DNA methylation at the Fkbp5 promoter (Lee et al., 2010). In this study, 
DEX-induced up-regulation of GLT-1 transcription was not associated with a change of DNA 
methylation at the distal promoter in CTX astrocytes. However, AcH4 levels at the GLT-1 
promoter notably correlated with an increased GLT-1 gene activity after DEX treatment. In 
line with data presented here, changes in H4 acetylation status elicited by DEX at several 
gene promoters in a natural killer cell line reflect alterations in expression of respective 
genes (Krukowski et al., 2011).  
Plasticity of chromatin marks at the CpG shore region in response to pharmacological 
stimulation was even more pronounced in CTX astrocytes exposed to HDAC-Is than to DEX. 
VPA treatment of CTX glia was accompanied by DNA demethylation of the GLT-1 shore 
region, enrichment in AcH4 and concomitant increase in GLT-1 gene activity. With this data, 
previously published findings on increased GLT-1 expression upon HDAC-I treatment were 
complemented (Allritz et al., 2009; Hassel et al., 2001), demonstrating that HDAC-I-induced 
GLT-1 gene activity could be mediated, at least partially, by chromatin changes at the 
promoter region. Surprisingly, VPA-induced hyperacetylation of H4 was also detected at the 
same GLT-1 region in CER astrocytes despite reduced GLT-1 mRNA levels. Many studies, 
including this one, show association of AcH4 and gene activity but there are also notable 
exceptions (Deckert and Struhl, 2001; Kurdistani et al., 2004; Wang et al., 2009). In addition, 
proteins with bromodomains are essential parts of some repressor complexes and they 
could mediate their binding to hyperacetylated H4 (Tae et al., 2011; Xhemalce and 
Kouzarides, 2010). Thus, in CER astrocytes, HDAC-Is might elicit cell type-specific synthesis 
of a repressor that operates with hyperacetylated AcH4 at GLT-1 endogenous gene locus, 
but not on the ectopic template.  
Previous studies have also demonstrated that HDAC inhibition by VPA triggers 
hyperacetylation and the loss of the DNA methylation at gene promoters leading to their 
(re)activation (Detich et al., 2003; Dong et al., 2008). These changes associated with VPA 
treatment are not confined to small number of gene loci. Rather, they reach genome-wide 
magnitudes reflected by reprogramming of genome expression and global changes in DNA 
demethylation as well as H3K9 hyperacetylation (Hezroni et al., 2011; Milutinovic et al., 
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2007). The results of this thesis demonstrate that VPA induces strong and reversible global 
H3/H4 hyperacetylation accompanied by transient demethylation at CCpGG sites in 
astrocytes from CTX and HPC. The similarity of TSA action on measured epigenetic 
parameters argues that HDAC inhibitory properties of VPA are attributable to effects of this 
drug. Moreover, D'Alessio et al. demonstrated that histone acetylation is one of the 
prerequisites for triggering DNA demethylation (D'Alessio et al., 2007) but the mechanism 
remains unknown. Several studies reported a functional interaction between HDACs and 
DNMTs (Deplus et al., 2002; Fuks et al., 2000). Even more, it has been demonstrated that 
the HDAC-Is VPA, TSA and apicidin down-regulate expression of DNMT subtypes in 
transformed cells (Arzenani et al., 2011; Kundakovic et al., 2009; You et al., 2008), offering a 
putative explanation for their demethylating activity. However, the results of this thesis 
showed that neither VPA nor TSA reduced levels of DNMT1 protein in primary astrocytes. 
Tumour cells are much more sensitive to HDAC-Is than normal cells (Bolden et al., 2006) 
which could explain the observed differences. Also, the differences in expression of 
GADD45α protein between untreated and TSA/VPA-treated CTX astrocytes were not 
detected. This protein, involved in DNA repair and cell-cycle control, is one of major 
candidates in replication-independent active DNA demethylation (Barreto et al., 2007; 
Schmitz et al., 2009). Nevertheless, the data reported here confirm the notion that DNA 
demethylation in VPA-treated primary astrocytes occurs in cells with very low replicative 
activity (Detich et al., 2003), but through a mechanism unrelated to decrease in GADD45α 
levels. However, it can not be excluded that sensitivity of the applied method for 
determination of protein levels may not suffice to detect subtle alterations in GADD45 levels 
which could account for slight changes in CCpGG methylation induced by HDAC-Is.  
Another mood stabilizer CBZ was reported to inhibit HDAC3 and HDAC7 in a cancer cell line 
at concentrations typically achieved in patients (Beutler et al., 2005). Changes in levels of 
global H3/H4 acetylation by applying CBZ at reported therapeutic range for 24 hours in 
primary astrocytes were not found, suggesting a cell type-specific effect. Similarly, another 
tested mood stabilizer LTG as well as the antidepressants AMI, VEN and CIT and failed to 
induce detectable changes in global histone acetylation levels. Excitingly, treatment with the 
tricyclic antidepressant AMI led to a slight reduction of genome-wide DNA methylation levels 
at CCpGG sites in CTX astrocytes. Like in the case of VPA, induced DNA demethylation 
was not accompanied with altered DNMT1 protein levels. However, AMI significantly 
reduced DNMT activity in treated astrocytes. A follow-up study demonstrated that this 
inhibitory effect was restricted to DNMT1 subtype and was also observed after treatment 
with structurally unrelated antidepressant paroxetine (PAR) (Zimmermann et al., submitted). 
Importantly, diminished DNMT1 activity by AMI and PAR was accompanied by a decrease in 
levels of G9a, which is a histone H3 Lys9 HMT (Tachibana et al., 2001) and an interaction 
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partner of DNMT1 (Esteve et al., 2006). In this thesis, a decline in H3K9 levels after 24 hours 
of treatment with AMI in CTX astrocytes was not detected. In a study by Zimmermann et al., 
a slight reduction of G9a protein levels by AMI at this time point was measured but this may 
not be sufficient to decrease global H3K9 methylation. Also, at least several known proteins 
have H3K9 methyltransferase activity (O'Carroll et al., 2000; Rea et al., 2000; Schotta et al., 
2004), thus making it difficult to detect alterations of global H3K9 caused by reduced G9a 
levels. Nevertheless, these results raise the possibility that AMI might alleviate disease 
symptoms by interfering with chromatin-remodelling machinery.  
Although AMI induced global DNA demethylation, the GLT-1 promoter was not affected and 
the level of expression remained unchanged. A recent study showed that co-administration 
of picomolar concentrations of AMI with morphine for 5 days increases GLT-1 expression in 
the spinal cord dorsal horn (Tai et al., 2008). Authors reported that AMI helped in restoration 
of decreased GLT-1 levels induced upon morphine infusion. The data presented in this 
thesis showed that LTG failed to demethylate GLT-1 shore region and enhance GLT-1 
transcription. Except for VPA, treatment with other investigated psychoactive drugs also 
induced no alterations in GLT-1 mRNA levels. These results suggest that only VPA exerts 
fast-acting effects on GLT-1 transcription probably due to its prominent chromatin-modifying 
properties. However, it can be that long-term treatment of astrocytes or in vivo administration 
of psychoactive drugs in animals could have an effect on GLT-1 expression, like it was 
shown for clozapine and haloperidol (Melone et al., 2001; Schneider et al., 1998). 
Genome stability is to a great extent determined by a remarkable ability of cells to maintain 
and faithfully replicate specific epigenetic patterns. This ensures specific cell function and 
adequate responses to a variety of stimuli. The results of this thesis show that chromatin 
marks at the GLT-1 promoter in astrocytes may have a significant impact on basal GLT-1 
expression as well as on GLT-1 function in different brain regions under conditions of stress 
and HDAC inhibition. They demonstrate that chromatin modifications at the GLT-1 gene 
locus are susceptible to specific alterations despite their intrinsic stability. This epigenetic 
plasticity makes GLT-1 an accessible pharmacological target to drugs with HDAC inhibitory 
properties. An increase in GLT-1 expression might consecutively lead to modulation of 
glutamatergic signalling. Thus, normalisation of central neural circuits implicated in mood 
disorders could be, at last in part, ascribed to epigenetic effects of VPA on GLT-1 regulation, 
especially knowing the positive effects of this drug on GLT-1 expression in animals (Hassel 
et al., 2001). According to the result of this thesis, DNA demethylation by VPA and AMI 
shows gene selectivity. Treatment with AMI may impact multiple targets in astrocytes, other 
than GLT 1, one example being HMT G9a (Zimmermann et al., submitted). Thus, epigenetic 
changes elicited by VPA and AMI may have repercussions on the outcome of the therapy by 
affecting astrocyte-neuron communication. 
 
References 
 23 
6  References 
 
Allritz C, Bette S, Figiel M, Engele J (2009) Endothelin-1 reverses the histone deacetylase 
inhibitor-induced increase in glial glutamate transporter transcription without affecting histone 
acetylation levels. Neurochemistry International 55:22-27. 
Allritz C, Bette S, Figiel M, Engele J (2010) Comparative structural and functional analysis of 
the GLT-1/EAAT-2 promoter from man and rat. Journal of Neuroscience Research 
88:1234-1241. 
Altar CA, Vawter MP, Ginsberg SD (2009) Target identification for CNS diseases by 
transcriptional profiling. Neuropsychopharmacology 34:18-54. 
Arriza JL, Eliasof S, Kavanaugh MP, Amara SG (1997) Excitatory amino acid transporter 5, 
a retinal glutamate transporter coupled to a chloride conductance. Proceedings of the 
National Academy of Sciences of the United States of America 94:4155-4160. 
Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG (1994) 
Functional comparisons of 3 glutamate transporter subtypes cloned from human motor 
cortex. Journal of Neuroscience 14:5559-5569. 
Arzenani MK, Zade AE, Ming Y, Vijverberg SJH, Zhang Z, Khan Z, Sadique S, Kallenbach L, 
Hu LF, Vukojevic V, Ekstrom TJ (2011) Genomic DNA hypomethylation by histone 
deacetylase inhibition implicates DNMT1 nuclear dynamics. Molecular and Cellular Biology 
31:4119-4128. 
Asano H, Aonuma M, Sanosaka T, Kohyama J, Namihira M, Nakashima K (2009) Astrocyte 
differentiation of neural precursor cells is enhanced by retinoic acid through a change in 
epigenetic modification. Stem Cells 27:2744-2752. 
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM 
(2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. 
Nature 475:91-95. 
Autry AE, Grillo CA, Piroli GG, Rothstein JD, Mcewen BS, Reagan LP (2006) Glucocorticoid 
regulation of GLT-1 glutamate transporter isoform expression in the rat hippocampus. 
Neuroendocrinology 83:371-379. 
References 
 24 
Bapat SA, Jin V, Berry N, Balch C, Sharma N, Kurrey N, Zhang S, Fang F, Lan X, Li M, 
Kennedy B, Bigsby RM, Huang THM, Nephew KP (2010) Multivalent epigenetic marks 
confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. 
Epigenetics 5:716-729. 
Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, Doderlein G, 
Maltry N, Wu W, Lyko F, Niehrs C (2007) Gadd45a promotes epigenetic gene activation by 
repair-mediated DNA demethylation. Nature 445:671-675. 
Baylin SB (2002) Mechanisms underlying epigenetically mediated gene silencing in cancer. 
Seminars in Cancer Biology 12:331-337. 
Berger SL (2001) An embarrassment of niches: the many covalent modifications of histones 
in transcriptional regulation. Oncogene 20:3007-3013. 
Berger UV, DeSilva TM, Chen WZ, Rosenberg PA (2005) Cellular and subcellular mRNA 
localization of glutamate transporter isoforms GLT1a and GLT1b in rat brain by in situ 
hybridization. Journal of Comparative Neurology 492:78-89. 
Bette S, Unger T, Lakowa N, Friedrich M, Engele J (2011) Sequences of the non-coding 
RNA, NTAB, are contained within the 3'-UTR of human and rat EAAT2/GLT-1 transcripts 
and act as transcriptional enhancers. Cellular and Molecular Neurobiology 31:393-399. 
Beutler AS, Li SD, Nicol R, Walsh MJ (2005) Carbamazepine is an inhibitor of histone 
deacetylases. Life Sciences 76:3107-3115. 
Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321:209-213. 
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase 
inhibitors. Nature Reviews Drug Discovery 5:769-784. 
Bourc'his D, Bestor TH (2004) Meiotic catastrophe and retrotransposon reactivation in male 
germ cells lacking Dnmt3L. Nature 431:96-99. 
Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A, 
Cedar H (1994) Sp1 elements protect a CpG island from de novo methylation. Nature 
371:435-438. 
Brinkman AB, Pennings SWC, Braliou GG, Rietveld LEG, Stunnenberg HG (2007) DNA 
methylation immediately adjacent to active histone marking does not silence transcription. 
Nucleic Acids Research 35:801-811. 
References 
 25 
Brito VI, Rozanski VE, Beyer C, Kuppers E (2009) Dopamine regulates the expression of the 
glutamate transporter GLT1 but not GLAST in developing striatal astrocytes. Journal of 
Molecular Neuroscience 39:372-379. 
Campanero MR, Armstrong MI, Flemington EK (2000) CpG methylation as a mechanism for 
the regulation of E2F activity. Proceedings of the National Academy of Sciences of the 
United States of America 97:6481-6486. 
Carson MJ, Thomas EA, Danielson PE, Sutcliffe JG (1996) The 5-HT5A serotonin receptor 
is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A 
mechanism for neuronal suppression of reactive astrocytes. Glia 17:317-326. 
Cervoni N, Szyf M (2001) Demethylase activity is directed by histone acetylation. Journal of 
Biological Chemistry 276:40778-40787. 
Chen TP, Ueda Y, Dodge JE, Wang ZJ, Li E (2003) Establishment and maintenance of 
genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. 
Molecular and Cellular Biology 23:5594-5605. 
Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR (2002) On the epigenetic regulation 
of the human reelin promoter. Nucleic Acids Research 30:2930-2939. 
Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 
1:623-634. 
Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE, 
Akil H, Watson SJ, Jones EG (2005) Altered cortical glutamatergic and GABAergic signal 
transmission with glial involvement in depression. Proceedings of the National Academy of 
Sciences of the United States of America 102:15653-15658. 
D'Alessio AC, Szyf M (2006) Epigenetic tete-a-tete: the bilateral relationship between 
chromatin modifications and DNA methylation. Biochemistry and Cell Biology-Biochimie et 
Biologie Cellulaire 84:463-476. 
D'Alessio AC, Weaver ICG, Szyf M (2007) Acetylation-induced transcription is required for 
active DNA demethylation in methylation-silenced genes. Molecular and Cellular Biology 
27:7462-7474. 
Deckert J, Struhl K (2001) Histone acetylation at promoters is differentially affected by 
specific activators and repressors. Molecular and Cellular Biology 21:2726-2735. 
References 
 26 
Deplus R, Brenner C, Burgers WA, Putmans P, Kouzarides T, de Launoit Y, Fuks F (2002) 
Dnmt3L is a transcriptional repressor that recruits histone deacetylase. Nucleic Acids 
Research 30:3831-3838. 
Detich N, Bovenzi V, Szyf M (2003) Valproate induces replication-independent active DNA 
demethylation. Journal of Biological Chemistry 278:27586-27592. 
Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho JS, 
Loewer S, Miller J, Schlaeger T, Daley GQ, Feinberg AP (2009) Differential methylation of 
tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem 
cells, embryonic stem cells and fibroblasts. Nature Genetics 41:1350-1353. 
Dong E, Nelson M, Grayson DR, Costa E, Guidotti A (2008) Clozapine and sulpiride but not 
haloperidol or olanzapine activate brain DNA demethylation. Proceedings of the National 
Academy of Sciences of the United States of America 105:13614-13619. 
Durrin LK, Mann RK, Kayne PS, Grunstein M (1991) Yeast histone H4 N-terminal sequence 
is required for promoter activation in vivo. Cell 65:1023-1031. 
Eberharter A, Becker PB (2002) Histone acetylation: a switch between repressive and 
permissive chromatin: Second in review series on chromatin dynamics. EMBO Reports 
3:224-229. 
Erhardt S, Su IH, Schneider R, Barton S, Bannister AJ, Perez-Burgos L, Jenuwein T, 
Kouzarides T, Tarakhovsky A, Surani MA (2003) Consequences of the depletion of zygotic 
and embryonic enhancer of zeste 2 during preimplantation mouse development. 
Development 130:4235-4248. 
Espinas ML, Roux J, Ghysdael J, Pictet R, Grange T (1994) Participation of EST 
transcription factors in the glucocorticoid response of the rat tyrosine aminotransferase gene. 
Molecular and Cellular Biology 14:4116-4125. 
Esteve PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, Carey MF, 
Pradhan S (2006) Direct interaction between DNMT1 and G9a coordinates DNA and histone 
methylation during replication. Genes & Development 20:3089-3103. 
Fagiolini M, Jensen CL, Champagne FA (2009) Epigenetic influences on brain development 
and plasticity. Current Opinion in Neurobiology 19:207-212. 
References 
 27 
Fairman WA, Vandenberg RJ, Arriza JL, Kavanaugh MP, Amara SG (1995) An excitatory 
amino acid transporter with properties of a ligand-gated chloride channel. Nature 
375:599-603. 
Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J (2003) Regulation of glial glutamate 
transporter expression by growth factors. Experimental Neurology 183:124-135. 
Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T (2000) DNA 
methyltransferase Dnmt1 associates with histone deacetylase activity. Nature Genetics 
24:88-91. 
Fuks F, Hurd PJ, Wolf D, Nan XS, Bird AP, Kouzarides T (2003) The methyl-CpG-binding 
protein MeCP2 links DNA methylation to histone methylation. Journal of Biological Chemistry 
278:4035-4040. 
Furuta A, Martin LJ, Lin CLG, DykesHoberg M, Rothstein JD (1997a) Cellular and synaptic 
localization of the neuronal glutamate transporters excitatory amino acid transporter 3 and 4. 
Neuroscience 81:1031-1042. 
Furuta A, Rothstein JD, Martin LJ (1997b) Glutamate transporter protein subtypes are 
expressed differentially during rat CNS development. Journal of Neuroscience 
17:8363-8375. 
Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, 
Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors 
inducing differentiation of transformed cells. EMBO Journal 20:6969-6978. 
Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 
389:349-352. 
Guo JU, Su YJ, Zhong C, Ming GL, Song HJ (2011) Hydroxylation of 5-methylcytosine by 
TET1 promotes active DNA demethylation in the adult brain. Cell 145:423-434. 
Halassa MM, Haydon PG (2010) Integrated brain circuits: astrocytic networks modulate 
neuronal activity and behavior. Annual Review of Physiology 72:335-355. 
Hassel B, Iversen EG, Gjerstad L, Tauboll E (2001) Up-regulation of hippocampal glutamate 
transport during chronic treatment with sodium valproate. Journal of Neurochemistry 
77:1285-1292. 
References 
 28 
Hatada I, Namihira M, Morita S, Kimura M, Horii T, Nakashima K (2008) Astrocyte-specific 
genes are generally demethylated in neural precursor cells prior to astrocytic differentiation. 
PloS ONE 3: e3189. 
Heintzman ND, et al. (2009) Histone modifications at human enhancers reflect global 
cell-type-specific gene expression. Nature 459:108-112. 
Hezroni H, Sailaja BS, Meshorer E (2011) Pluripotency-related, valproic acid (VPA)-induced 
genome-wide histone H3 Lysine 9 (H3K9) acetylation patterns in embryonic stem cells. 
Journal of Biological Chemistry 286:35977-35988. 
Hirabayashi Y, Gotoh Y (2010) Epigenetic control of neural precursor cell fate during 
development. Nature Reviews Neuroscience 11:377-388. 
Holmseth S, Scott HA, Real K, Lehre KP, Leergaard TB, Bjaalie JG, Danbolt NC (2009) The 
concentrations and distributions of three C-terminal variants of the Glt1 (Eaat2; Slc1A2) 
glutamate transporter protein in rat brain tissue suggest differential regulation. Neuroscience 
162:1055-1071. 
Iguchiariga SMM, Schaffner W (1989) CpG methylation of the cAMP-responsive enhancer 
promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional 
activation. Genes & Development 3:612-619. 
Irizarry RA, Ladd-Acosta C, Wen B, Wu ZJ, Montano C, Onyango P, Cui HM, Gabo K, 
Rongione M, Webster M, Ji H, Potash JB, Sabunciyan S, Feinberg AP (2009) The human 
colon cancer methylome shows similar hypo- and hypermethylation at conserved 
tissue-specific CpG island shores. Nature Genetics 41:178-186. 
Jackson M, Krassowska A, Gilbert N, Chevassut T, Forrester L, Ansell J, Ramsahoye B 
(2004) Severe global DNA hypomethylation blocks differentiation and induces histone 
hyperacetylation in embryonic stem cells. Molecular and Cellular Biology 24:8862-8871. 
Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RWC, Baylin SB, Schuebel KE 
(2006) De novo CpG island methylation in human cancer cells. Cancer Research 
66:682-692. 
Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074-1080. 
References 
 29 
Ji YF, Xu SM, Zhu J, Wang XX, Shen Y (2011) Insulin increases glutamate transporter GLT1 
in cultured astrocytes. Biochemical and Biophysical Research Communications 
405:691-696. 
Jones PL, Veenstra GJC, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, 
Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress 
transcription. Nature Genetics 19:187-191. 
Jost JP (1993) Nuclear extracts of chicken embryos promote an active demethylation of 
DNA by excision repair of 5-methyldeoxycytidine. Proceedings of the National Academy of 
Sciences of the United States of America 90:4684-4688. 
Jurkowska RZ, Rajavelu A, Anspach N, Urbanke C, Jankevicius G, Ragozin S, Nellen W, 
Jeltsch A (2011) Oligomerization and binding of the Dnmt3a DNA methyltransferase to 
parallel DNA molecules: Heterochromatic localisation and role of Dnmt3L. Journal of 
Biological Chemistry 286:24200-24207. 
Kanai Y, Hediger MA (1992) Primary structure and functional characterization of a 
high-affinity glutamate transporter. Nature 360:467-471. 
Kim MS, Kondo T, Takada I, Youn MY, Yamamoto Y, Takahashi S, Matsumoto T, 
Fujiyama S, Shirode Y, Yamaoka I, Kitagawa H, Takeyama KI, Shibuya H, Ohtake F, Kato S 
(2009) DNA demethylation in hormone-induced transcriptional derepression. Nature 
461:1007-1012. 
Krukowski K, Eddy J, Kosik KL, Konley T, Janusek LW, Mathews HL (2011) Glucocorticoid 
dysregulation of natural killer cell function through epigenetic modification. Brain Behavior 
and Immunity 25:239-249. 
Kundakovic M, Chen Y, Guidotti A, Grayson DR (2009) The reelin and GAD67 promoters 
are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. 
Molecular Pharmacology 75:342-354. 
Kurdistani SK, Tavazoie S, Grunstein M (2004) Mapping global histone acetylation patterns 
to gene expression. Cell 117:721-733. 
Lachner M, Jenuwein T (2002) The many faces of histone lysine methylation. Current 
Opinion in Cell Biology 14:286-298. 
References 
 30 
Lee RS, Tamashiro KLK, Yang XJ, Purcell RH, Harvey A, Willour VL, Huo YQ, Rongione M, 
Wand GS, Potash JB (2010) Chronic corticosterone exposure increases expression and 
decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 
151:4332-4343. 
Leonhardt H, Page AW, Weier HU, Bestor TH (1992) A targeting sequence directs DNA 
methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71:865-873. 
Li LB, Toan SV, Zelenaia O, Watson DJ, Wolfe JH, Rothstein JD, Robinson MB (2006) 
Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective 
transcriptional effect on the GLT-1/EAAT2 subtype. Journal of Neurochemistry 97:759-771. 
Liang GG, Chan MF, Tomigahara Y, Tsai YC, Gonzales FA, Li E, Laird PW, Jones PA 
(2002) Cooperativity between DNA methyltransferases in the maintenance methylation of 
repetitive elements. Molecular and Cellular Biology 22:480-491. 
Lock LF, Takagi N, Martin GR (1987) Methylation of the Hprt gene on the inactive X occurs 
after chromosome inactivation. Cell 48:39-46. 
Maragakis NJ, Rothstein JD (2004) Glutamate transporters: animal models to neurologic 
disease. Neurobiology of Disease 15:461-473. 
Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan GP, Sun YE (2003) DNA 
methylation-related chromatin remodeling in activity-dependent Bdnf gene regulation. 
Science 302:890-893. 
Meaney MJ (2010) Epigenetics and the biological definition of gene x environment 
interactions. Child Development 81:41-79. 
Melone M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, Perez-Samartin A, Matute C, 
Cozzi A, Pellegrini-Giampietro DE, Rothstein JD, Conti F (2001) The expression of 
glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic 
drug clozapine. Molecular Psychiatry 6:380-386. 
Mendenhall EM, Koche RP, Truong T, Zhou VW, Issac B, Chi AS, Ku M, Bernstein BE 
(2010) GC-rich sequence elements recruit PRC2 in mammalian ES cells. PloS Genetics 6: 
e1001244. 
References 
 31 
Milutinovic S, D'Alessio AC, Detich N, Szyf M (2007) Valproate induces widespread 
epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 
28:560-571. 
Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M, Schubeler D 
(2008) Lineage-specific polycomb targets and de novo DNA methylation define restriction 
and potential of neuronal progenitors. Molecular Cell 30:755-766. 
Monti B, Polazzi E, Contestabile A (2009) Biochemical, molecular and epigenetic 
mechanisms of valproic acid neuroprotection. Current Molecular Pharmacology 2:95-109. 
Mosammaparast N, Shi Y (2010) Reversal of histone methylation: biochemical and 
molecular mechanisms of histone demethylases. Annual Review of Biochemistry 
79:155-179. 
Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmuhl Y, Fischer D, Holsboer F, Wotjak CT, 
Almeida OFX, Spengler D (2009) Dynamic DNA methylation programs persistent adverse 
effects of early-life stress. Nature Neuroscience 12:1559-1566. 
Nan XS, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A (1998) 
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone 
deacetylase complex. Nature 393:386-389. 
Nimura K, Ura K, Kaneda Y (2010) Histone methyltransferases: regulation of transcription 
and contribution to human disease. Journal of Molecular Medicine 88:1213-1220. 
O'Carroll D, Scherthan H, Peters AHFM, Opravil S, Haynes AR, Laible G, Rea S, Schmid M, 
Lebersorger A, Jerratsch M, Sattler L, Mattei MG, Denny P, Brown SDM, Schweizer D, 
Jenuwein T (2000) Isolation and characterization of Suv39h2, a second histone H3 
methyltransferase gene that displays testis-specific expression. Molecular and Cellular 
Biology 20:9423-9433. 
Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are 
essential for de novo methylation and mammalian development. Cell 99:247-257. 
Ooi SKT, Qiu C, Bernstein E, Li KQ, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, 
Lin SP, Allis CD, Cheng XD, Bestor TH (2007) DNMT3L connects unmethylated lysine 4 of 
histone H3 to de novo methylation of DNA. Nature 448:714-717. 
 
References 
 32 
Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA, Oliet SHR 
(2006) Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 
125:775-784. 
Pawlak J, Brito V, Kuppers E, Beyer C (2005) Regulation of glutamate transporter GLAST 
and GLT-1 expression in astrocytes by estrogen. Molecular Brain Research 138:1-7. 
Perea G, Araque A (2007) Astrocytes potentiate transmitter release at single hippocampal 
synapses. Neuron Glia Biology 2:S142-S143. 
Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone 
deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and 
teratogen. Journal of Biological Chemistry 276:36734-36741. 
Pines G, Danbolt NC, Bjoras M, Zhang YM, Bendahan A, Eide L, Koepsell H, 
Stormmathisen J, Seeberg E, Kanner BI (1992) Cloning and expression of a rat brain 
L-glutamate transporter. Nature 360:464-467. 
Plachez C, Martin A, Guiramand J, Recasens M (2004) Astrocytes repress the neuronal 
expression of GLAST and GLT glutamate transporters in cultured hippocampal neurons from 
embryonic rats. Neurochemistry International 45:1113-1123. 
Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, 
Rolfe PA, Herbolsheimer E, Zeitlinger J, Lewitter F, Gifford DK, Young RA (2005) 
Genome-wide map of nucleosorne acetylation and methylation in yeast. Cell 122:517-527. 
Rajkowska G (2000) Postmortem studies in mood disorders indicate altered numbers of 
neurons and glial cells. Biological Psychiatry 48:766-777. 
Rauen T, Wiessner M, Sullivan R, Lee A, Pow DV (2004) A new GLT1 splice variant: cloning 
and immunolocalization of GLT1c in the mammalian retina and brain. Neurochemistry 
International 45:1095-1106. 
Rea S, Eisenhaber F, O'Carroll N, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, 
Ponting CP, Allis CD, Jenuwein T (2000) Regulation of chromatin structure by site-specific 
histone H3 methyltransferases. Nature 406:593-599. 
 
 
References 
 33 
Reagan LP, Rosell DR, Wood GE, Spedding M, Munoz C, Rothstein J, Mcewen BS (2004) 
Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat 
hippocampus: Reversal by tianeptine. Proceedings of the National Academy of Sciences of 
the United States of America 101:2179-2184. 
Reuss B, Dermietzel R, Unsicker K (1998) Fibroblast growth factor 2 (FGF-2) differentially 
regulates connexin (cx) 43 expression and function in astroglial cells from distinct brain 
regions. Glia 22:19-30. 
Reuss B, Hertel M, Werner S, Unsicker K (2000) Fibroblast growth factors-5 and-9 distinctly 
regulate expression and function of the gap junction protein connexin43 in cultured astroglial 
cells from different brain regions. Glia 30:231-241. 
Rodriguez-Kern A, Gegelashvili M, Schousboe A, Zhang J, Sung L, Gegelashvili G (2003) 
Beta-amyloid and brain-derived neurotrophic factor, BDNF, up-regulate the expression of 
glutamate transporter GLT-1/EAAT2 via different signaling pathways utilizing transcription 
factor NF-kappa B. Neurochemistry International 43:363-370. 
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Hoberg MD, 
Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB (2005) Beta-lactam 
antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 
433:73-77. 
Rountree MR, Bachman KE, Baylin SB (2000) DNMT1 binds HDAC2 and a new 
co-repressor, DMAP1, to form a complex at replication foci. Nature Genetics 25:269-277. 
Sales AJ, Biojone C, Terceti MS, Guimaraes FS, Gomes MVM, Joca SRL (2011) 
Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA 
methylation inhibitors. British Journal of Pharmacology 164:1711-1721. 
Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, 
Mason GF (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in 
patients with major depression. Archives of General Psychiatry 61:705-713. 
Sarma K, Reinberg D (2005) Histone variants meet their match. Nature Reviews Molecular 
Cell Biology 6:139-149. 
Schlag BD, Vondrasek JR, Munir M, Kalandadze A, Zelenaia OA, Rothstein JD, 
Robinson MB (1998) Regulation of the glial Na+-dependent glutamate transporters by cyclic 
AMP analogs and neurons. Molecular Pharmacology 53:355-369. 
References 
 34 
Schluter K, Figiel M, Rozyczka J, Engele J (2002) CNS region-specific regulation of glial 
glutamate transporter expression. European Journal of Neuroscience 16:836-842. 
Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, Rehli M (2009) 
Lineage-specific DNA methylation in T cells correlates with histone methylation and 
enhancer activity. Genome Research 19:1165-1174. 
Schmitz KM, Schmitt N, Hoffmann-Rohrer U, Schafer A, Grummt I, Mayer C (2009) TAF12 
recruits Gadd45a and the nucleotide excision repair complex to the promoter of rRNA genes 
leading to active DNA demethylation. Molecular Cell 33:344-353. 
Schneider JS, Wade T, Lidsky TI (1998) Chronic neuroleptic treatment alters expression of 
glial glutamate transporter GLT-1 mRNA in the striatum. NeuroReport 9:133-136. 
Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T 
(2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive 
heterochromatin. Genes & Development 18:1251-1262. 
Schroeder FA, Lin CL, Crusio WE, Akbarian S (2007) Antidepressant-like effects of the 
histone deacetylase inhibitor, sodium butyrate, in the mouse. Biological Psychiatry 62:55-64. 
Shen SM, Li JD, Casaccia-Bonnefil P (2005) Histone modifications affect timing of 
oligodendrocyte progenitor differentiation in the developing rat brain. Journal of Cell Biology 
169:577-589. 
Shimabukuro M, Jinno Y, Fuke C, Okazaki Y (2006) Haloperidol treatment induces tissue- 
and sex-specific changes in DNA methylation: a control study using rats. Behavioral and 
Brain Functions 2:37. 
Sitcheran R, Gupta P, Fisher PB, Baldwin AS (2005) Positive and negative regulation of 
EAAT2 by NF-kappa B: a role for N-myc in TNF alpha-controlled repression. EMBO Journal 
24:510-520. 
Song MR, Ghosh A (2004) FGF2-induced chromatin remodeling regulates CNTF-mediated 
gene expression and astrocyte differentiation. Nature Neuroscience 7:229-235. 
Spencer VA, Davie JR (1999) Role of covalent modifications of histones in regulating gene 
expression. Gene 240:1-12. 
References 
 35 
Stein R, Razin A, Cedar H (1982) In vitro methylation of the hamster adenine 
phosphoribosyltransferase gene inhibits its expression in mouse L-cells. Proceedings of the 
National Academy of Sciences of the United States of America 79:3418-3422. 
Storck T, Schulte S, Hofmann K, Stoffel W (1992) Structure, expression, and functional 
analysis of a Na+-dependent glutamate aspartate transporter from rat brain. Proceedings of 
the National Academy of Sciences of the United States of America 89:10955-10959. 
Swisher JFA, Rand E, Cedar H, Pyle AM (1998) Analysis of putative RNase sensitivity and 
protease insensitivity of demethylation activity in extracts from rat myoblasts. Nucleic Acids 
Research 26:5573-5580. 
Tachibana M, Sugimoto K, Fukushima T, Shinkai Y (2001) SET domain-containing protein, 
G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity 
and specific selectivity to lysines 9 and 27 of histone H3. Journal of Biological Chemistry 
276:25309-25317. 
Tae S, Karkhanis V, Velasco K, Yaneva M, Erdjument-Bromage H, Tempst P, Sif S (2011) 
Bromodomain protein 7 interacts with PRMT5 and PRC2, and is involved in transcriptional 
repression of their target genes. Nucleic Acids Research 39:5424-5438. 
Tai YH, Tsai RY, Wang YH, Cherng CH, Tao PL, Liu TM, Wong CS (2008) Amitriptyline 
induces nuclear transcription factor-kappa B-dependent glutamate transporter upregulation 
in chronic morphine-in fused rats. Neuroscience 153:823-831. 
Takizawa T, Nakashima K, Namihira M, Ochiai W, Uemura A, Yanagisawa M, Fujita N, 
Nakao M (2001) DNA methylation is a critical cell-intrinsic determinant of astrocyte 
differentiation in the fetal brain. Developmental Cell 1:749-758. 
Tamaru H, Selker EU (2001) A histone H3 methyltransferase controls DNA methylation in 
Neurospora crassa. Nature 414:277-283. 
Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, 
Nishikawa T, Ichihara N, Hori S, Takimoto M, Wada K (1997) Epilepsy and exacerbation of 
brain injury in mice lacking the glutamate transporter GLT-1. Science 276:1699-1702. 
Tian GL, Lai LC, Guo H, Lin Y, Butchbach MER, Chang YM, Lin CLG (2007) Translational 
control of glial glutamate transporter EAAT2 expression. Journal of Biological Chemistry 
282:1727-1737. 
References 
 36 
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006) Sustained 
hippocampal chromatin regulation in a mouse model of depression and antidepressant 
action. Nature Neuroscience 9:519-525. 
Tshuikina M, Nilsson K, Oberg F (2008) Positive histone marks are associated with active 
transcription from a methylated ICSBP/IRF8 gene. Gene 410:259-267. 
Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T, Suzuki T, Miyata N, 
Watanabe Y (2011) Epigenetic status of GDNF in the ventral striatum determines 
susceptibility and adaptation to daily stressful events. Neuron 69:359-372. 
van der Laan S, de Kloet ER, Meijer OC (2009) Timing is critical for effective glucocorticoid 
receptor mediated repression of the cAMP-induced CRH gene. PloS ONE 4: e4327. 
Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, 
Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F (2006) 
The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874. 
Wang DQ, Xia XM, Liu Y, Oetting A, Walker RL, Zhu YL, Meltzer P, Cole PA, Shi YB, 
Yen PM (2009) Negative regulation of TSH alpha target gene by thyroid hormone involves 
histone acetylation and corepressor complex dissociation. Molecular Endocrinology 
23:600-609. 
Wang GJ, Chung HJ, Schnuer J, Pratt K, Zable AC, Kavanaugh MP, Rosenberg PA (1998) 
High affinity glutamate transport in rat cortical neurons in culture. Molecular Pharmacology 
53:88-96. 
Weaver ICG, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl J, Dymov S, 
Szyf M, Meaney MJ (2004) Epigenetic programming by maternal behavior. Nature 
Neuroscience 7:847-854. 
Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D (2007) 
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the 
human genome. Nature Genetics 39:457-466. 
Weiss A, Keshet I, Razin A, Cedar H (1996) DNA demethylation in vitro: Involvement of 
RNA. Cell 86:709-718. 
Xhemalce B, Kouzarides T (2010) A chromodomain switch mediated by histone H3 Lys 4 
acetylation regulates heterochromatin assembly. Genes & Development 24:647-652. 
References 
 37 
Yang YJ, Gozen O, Vidensky S, Robinson MB, Rothstein JD (2010) Epigenetic regulation of 
neuron-dependent induction of astroglial synaptic protein GLT1. Glia 58:277-286. 
Yeh TH, Lee DY, Gianino SM, Gutmann DH (2009) Microarray analyses reveal regional 
astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial 
proliferation. Glia 57:1239-1249. 
Yildiz-Yesiloglu A, Ankerst DP (2006) Neurochemical alterations of the brain in bipolar 
disorder and their implications for pathophysiology: A systematic review of the in vivo proton 
magnetic resonance spectroscopy findings. Progress in Neuro-Psychopharmacology & 
Biological Psychiatry 30:969-995. 
You JS, Kang JK, Lee EK, Lee JC, Lee SH, Jeon YJ, Koh DH, Ahn SH, Seo DW, Lee HY, 
Cho EJ, Han JW (2008) Histone deacetylase inhibitor apicidin downregulates DNA 
methyltransferase 1 expression and induces repressive histone modifications via recruitment 
of corepressor complex to promoter region in human cervix cancer cells. Oncogene 
27:1376-1386. 
Zelenaia O, Schlag BD, Gochenauer GE, Ganel R, Song W, Beesley JS, Grinspan JB, 
Rothstein JD, Robinson MB (2000) Epidermal growth factor receptor agonists increase 
expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on 
phosphatidylinositol 3-kinase and transcription factor NF-kappa B. Molecular Pharmacology 
57:667-678. 
 
Zschocke J, Allritz C, Engele J, Rein T (2007) DNA methylation dependent silencing of the 
human glutamate transporter EAAT2 gene in glial cells. Glia 55:663-674. 
 
Zschocke J, Bayatti N, Clement AM, Witan H, Figiel M, Engele J, Behl C (2005) Differential 
promotion of glutamate transporter expression and function by glucocorticoids in astrocytes 
from various brain regions. Journal of Biological Chemistry 280:34924-34932. 
 
Zimmermann N, Zschocke J, Perisic T, Yu S, Holsboer F, Rein T. Mechanisms of 
antidepressant actions on DNA methyltransferases. (submitted) 
 
 
 
Curriculum Vitae 
 38 
7  Curriculum Vitae 
 
Personal Information 
 
Name:                Tatjana 
Surname:            Perisic 
Date of birth:      1.12.1976 
Place of birth:     Travnik, Bosnia and Herzegovina 
 
Education 
 
06/07-present     PhD student at the Max Planck Institute of Psychiatry in Munich 
                           Chaperone Research Group, Dr. Theo Rein 
01/03-06/07        Research assistant and MSc student 
                           Institute for Biological Research (Department of Biochemistry) in Belgrade 
MSc thesis: “Alterations in glucocorticoid receptor function and heat shock 
protein expression in peripheral blood mononuclear cells of asthmatic 
children are associated with chronic inflammation” 
10/95-11/02        University education in Molecular Biology and Physiology 
                           Faculty of Biology, Belgrade University, Serbia 
 
Publication List 
 
Perisic T, Holsboer F, Rein T, Zschocke J (2012) The CpG island shore of the GLT-1 gene 
acts as a methylation-sensitive enhancer. Glia (in press) 
 
Zimmermann N, Zschocke J, Perisic T, Yu S, Holsboer F, Rein T. Mechanisms of 
antidepressant actions on DNA methyltransferases. (submitted) 
 
Matic G, Vojnovic Milutinovic D, Nestorov J, Elakovic I, Manitasevic Jovanovic S, Perisic T, 
Dundjerski J, Damjanovic S, Knezevic G, Spiric Z, Vermetten E, Savic D. Lymphocyte 
glucocorticoid receptor level and hormone binding properties discriminate between war 
related PTSD and resilience to PTSD. (submitted) 
 
Brkljacić J, Tanić N, Milutinović DV, Elaković I, Jovanović SM, Perisić T, Dundjerski J, 
Matić G (2010) Validation of endogenous controls for gene expression studies in peripheral 
lymphocytes from war veterans with and without PTSD. BMC Molecular Biology 11:26. 
 
Curriculum Vitae 
 39 
Perisic T, Zimmermann N, Kirmeier T, Asmus M, Tuorto F, Uhr M, Holsboer F, Rein T, 
Zschocke J (2010) Valproate and amitriptyline exert common and divergent influences on 
global and gene promoter-specific chromatin modifications in rat primary astrocytes. 
Neuropsychopharmacology 3:792-805.  
 
Perisić T, Srećković M, Matić G (2009) Modulation of glucocorticoid receptor function and 
expression in adolescent moderate asthma. Respiration 1:70-5.  
 
Perisić T, Srećković M, Matić G (2007) An imbalance in antioxidant enzymes and stress 
proteins in childhood asthma. Clinical Biochemistry 15:1168-71.  
 
Elaković I, Perisić T, Canković-Kadijević M, Matić G (2007) Correlation between 
glucocorticoid receptor binding parameters, blood pressure, and body mass index in a 
healthy human population. Cell Biochemistry and Function 4:427-31. 
 
Brkljacić J, Perisić T, Dundjerski J, Matić G (2007) Interaction of rat renal glucocorticoid 
receptor with Hsp90 and Hsp70 upon stress provoked by mercury. Journal of Applied 
Toxicology 1:43-50.  
 
Appendix 
 40 
8  Appendix 
 
This section contains reprints of the following articles: 
 
I  
Perisic T, Zimmermann N, Kirmeier T, Asmus M, Tuorto F, Uhr M, Holsboer F, Rein T, 
Zschocke J (2010) Valproate and amitriptyline exert common and divergent influences on 
global and gene promoter-specific chromatin modifications in rat primary astrocytes. 
Neuropsychopharmacology 3:792-805. 
 
II 
Perisic T, Holsboer F, Rein T, Zschocke J (2012) The CpG island shore of the GLT-1 gene 
acts as a methylation-sensitive enhancer. Glia (in press)  
 
Valproate and Amitriptyline Exert Common and Divergent
Influences on Global and Gene Promoter-Specific Chromatin
Modifications in Rat Primary Astrocytes
Tatjana Perisic1, Nicole Zimmermann1, Thomas Kirmeier1, Maria Asmus2, Francesca Tuorto3,4,
Manfred Uhr2, Florian Holsboer1,2, Theo Rein*,1,5 and Ju¨rgen Zschocke1,5
1Chaperone Research Group, Max-Planck-Institute of Psychiatry, Munich, Bavaria, Germany; 2Pharmacogenetics Group, Max-Planck-Institute of
Psychiatry, Munich, Bavaria, Germany; 3Division of Epigenetics, German Cancer Research Center, Heidelberg, Germany; 4Institute of Genetics
and Biophysics ‘A. Buzzati-Traverso’, CNR, Naples, Italy
Aberrant biochemical processes in the brain frequently go along with subtle shifts of the cellular epigenetic profile that might support the
pathogenic progression of psychiatric disorders. Although recent reports have implied the ability of certain antidepressants and mood
stabilizers to modulate epigenetic parameters, studies comparing the actions of these compounds under the same conditions are lacking.
In this study, we screened amitriptyline (AMI), venlafaxine, citalopram, as well as valproic acid (VPA), carbamazepine, and lamotrigine
for their potential actions on global and local epigenetic modifications in rat primary astrocytes. Among all drugs, VPA exposure
evoked the strongest global chromatin modifications, including histone H3/H4 hyperacetylation, 2MeH3K9 hypomethylation, and
DNA demethylation, as determined by western blot and luminometric methylation analysis, respectively. CpG demethylation occurred
independently of DNA methyltransferase (DNMT) suppression. Strikingly, AMI also induced slight cytosine demethylation, paralleled by
the reduction in DNMT enzymatic activity, without affecting the global histone acetylation status. Locally, VPA-induced chromatin
modifications were reflected at the glutamate transporter (GLT-1) promoter as shown by bisulfite sequencing and acetylated histone H4
chromatin immunoprecipitation analysis. Distinct CpG sites in the distal part of the GLT-1 promoter were demethylated and enriched in
acetylated histone H4 in response to VPA. For the first time, we could show that these changes were associated with an enhanced
transcription of this astrocyte-specific gene. In contrast, AMI failed to stimulate GLT-1 transcription and to alter promoter methylation
levels. In conclusion, VPA and AMI globally exerted chromatin-modulating activities using different mechanisms that divergently
precipitated at an astroglial gene locus.
Neuropsychopharmacology (2010) 35, 792–805; doi:10.1038/npp.2009.188; published online 18 November 2009
Keywords: antidepressant; glia; DNA methylation; GLT-1; histone acetylation; mood stabilizer
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INTRODUCTION
The vertebrate brain is exposed to a number of environ-
mental cues that are processed in an adaptive manner. These
adaptive processes form the basis of neuroplasticity, and are
characterized by often-persistent changes in neural gene
expression. Epigenetics represents an essential element for
transmitting environmental cues into altered neural mole-
cular pathways (Szyf et al, 2008). Frequently, epigenetic
chromatin modifications affect the acetylation or methylation
status of histones and the methylation of cytosine residues
within CpG dinucleotides. Histone acetylation and DNA
methylation show some degree of interdependency, although
a detailed analysis of this interaction is still pending
(D’Alessio and Szyf, 2006). Epigenetic modifications subs-
equently alter chromatin packaging, and, if occurring in the
proximity of gene promoters, exons or introns, either
promote or suppress gene transcription (Herman and Baylin,
2003). Enzymes catalyzing these epigenetic reactions belong
to the classes of histone acetyltransferases (HATs) and methyl-
transferases (HMTs), histone deacetylases (HDACs), and DNA
methyltransferases (DNMTs) (Ng and Bird, 1999).
Recently, it has been shown how external stimuli can be
translated into modified epigenetic marks for the example
of the brain-derived neurotrophic factor (BDNF) promoter
(Chen et al, 2003). After membrane depolarization on iso-
lated neurons, specific CpG dinucleotides within the BDNF
promoter underwent demethylation, accompanied by the
upregulation of gene transcription. Similarly, mRNA and
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protein levels of distinct DNMT subtypes were reduced
under similar conditions, which resulted in a diminished
activity of the respective enzymes (Sharma et al, 2008).
The consequence of an intrinsically false or inadequate
adaptation process in response to detrimental environ-
mental factors such as stress might go along with the
establishment of aberrant epigenetic signatures. In humans,
there is mounting evidence that epigenetic mechanisms are
involved in the pathophysiology of stress-related disorders,
including unipolar and bipolar depression (Mill and Petronis,
2007; Petronis, 2003). Postmortem studies of suicide victims
with a history of depression or childhood abuse showed
differential expression of DNMT subtypes (Poulter et al, 2008)
and promoter-wide hypermethylation of ribosomal RNA gene
promoters (McGowan et al, 2008), respectively. Humans who
experienced childhood abuse and committed suicide also
showed increased methylation of the neuron-specific gluco-
corticoid receptor (GR) promoter in the hippocampus
paralleled by reduced levels of the corresponding mRNA
transcripts (McGowan et al, 2009). In general, GR has a
pivotal role in balancing the hypothalamic pituitary axis
(HPA) in response to eg, stressful situations, and a HPA
imbalance is observed in various psychiatric disorders. In
rodents, it was recently shown that poor maternal care of the
offspring increased DNA methylation of the GR exon 17
promoter in the hippocampus and, thereby impaired negative
feedback regulation of HPA axis due to lower GR protein
levels (Weaver et al, 2004). Interestingly, application of an
HDAC inhibitor (HDAC-I) restored normal HPA response to
stress in the offspring. In addition, chronic social stress in
rodents led to distinct biochemical histone modifications
within the BDNF gene promoter, paralleled by a reduced
BDNF transcription (Tsankova et al, 2006).
Hence, pharmacological interference with the epigenetic
setup of the cell might represent an avenue to normalize the
aberrantly installed epigenetic profiles. So far, drug therapy
of patients suffering from bipolar and major depression is
based on the stabilization of neurotransmitter circuits that
involve the serotonergic, noradrenergic, glutamatergic, and
GABAergic system. Most of the therapeutic compounds
exert their beneficial effects after a latency period, indicat-
ing the necessity for preceding adaptive processes. This
raises the question, whether psychoactive substances
would potentially interfere directly or indirectly with the
epigenetic makeup of exposed cells. Indeed, the mood
stabilizer, valproic acid (VPA), was the first psycho-
active drug shown to exhibit HDAC inhibitory properties
(Gottlicher et al, 2001; Phiel et al, 2001). Another study
investigated antiepileptic drugs and identified topiramate
as an inhibitor of HDAC activity (Eyal et al, 2004).
In this study, we aimed to comprehensively analyze the
potential of frequently prescribed antidepressants, including
amitriptyline (AMI), venlafaxine (VEN), citalopram (CIT),
and mood stabilizers such as VPA, carbamazepine (CBZ), and
lamotrigine (LTG) to affect epigenetic parameters in astro-
cytes. Astrocytes represent the majority of cells within the
CNS, and modulate synaptic strength by their association with
synapses (Schipke and Kettenmann, 2004). In addition, astro-
cytes support neuronal function, as they produce neurotrophic
factors, including BDNF and glial-derived neurotrophic factor,
also in response to VPA exposure (Chen et al, 2006; Wu et al,
2008c). We monitored drug-induced global epigenetic changes
by measuring histone H3 and H4 acetylation/methylation,
as well as by DNA methylation. To explore whether global
changes would be also reflected at gene loci that are important
for astrocytic function, we selected the glutamate transporter
(GLT-1) promoter as a model gene.
MATERIALS AND METHODS
Primary Astrocyte Cell Culture
Enriched astroglial cultures were prepared from postnatal
day 1 rat pups (Sprague–Dawley, Charles River, Sulzfeld,
Germany) as described previously (Franke et al, 1998). In
these cultures, 90% of all cells represent type-1 astrocytes.
Briefly, the dissected cortical hemispheres and hippocam-
pus were trypsinized (Invitrogen, Merelbeke, Belgium);
trypsin action was terminated by adding Hanks’ balanced
salt solution (Invitrogen), supplemented with 10% fetal calf
serum. The tissue was passed through a serological pipette,
spun, and resuspended in modified Eagle’s medium (MEM,
Invitrogen) supplemented with 10% horse serum (Invitrogen).
After the third passage, the cells were maintained in a serum-
free (MEM/ Ham’s F-12, 1 : 1) N2-supplemented medium.
Pharmacological Treatment of Astrocytes
All experiments were carried out using third-passage astro-
cytic cells. Sodium butyrate (NaB), VPA, CBZ, LTG, AMI,
CIT, and trichostatin A (TSA) were purchased from Sigma
(Deisenhof, Germany). VEN was an industrial donation
(Wyeth Pharma GmbH, Mu¨nster, Germany). Stock solutions
of the drugs were prepared by dissolving the substances in
distilled water (VPA, NaB, AMI, CIT, VEN), 100% ethanol
(TSA), or DMSO (CBZ, LTG). When treating cells for 72 h,
the drug-containing medium was renewed after 48 h. For
washout experiments, after 72 h of treatment, the cells were
rinsed twice with the medium, and thereafter kept in the
absence of the drug for an additional 48 h.
Cellular Protein Extraction and Western Blot Analysis
Cells were lysed in the buffer containing 62.5mM Tris,
2% SDS, and 10% sucrose, supplemented with protease
inhibitor cocktail (Sigma). Samples were sonicated and
heated at 951C for 5min. Proteins were separated by
SDS-PAGE and electrotransferred onto nitrocellulose mem-
branes. Blots were placed in Tris-buffered saline, supple-
mented with 0.05% Tween (Sigma) and 5% non-fat milk for
1 h at room temperature, and then incubated with primary
antibody (diluted in TBS/0.05% Tween) overnight at 41C.
Subsequently, the blots were washed and probed with
the respective horseradish peroxidase-conjugated secondary
antibody for 1 h at room temperature. The immunoreactive
bands were visualized using the ECL detection reagent
(Millipore, Billerica, MA, USA). The following primary
antibodies were used: anti-acetyl-Histone H3 antibody
(recognizes acetylation at lysine 9; 1 : 2000; no. 06–942,
Upstate, Temecula, CA, USA), anti-acetyl-Histone H4
antibody (recognizes acetylation at lysines 5, 8, 12, and
16; 1 : 4000; no. 06–866, Upstate), anti-DNMT-1 (1 : 1000;
no. IMG-261A, IMGENEX, San Diego, CA, USA), anti-
GADD 45a (1 : 250; no. sc-6850, Santa Cruz Biotechnology,
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Heidelberg, Germany), anti-dimethyl-Histone H3 antibodies
(react with methylated histones on lysine 9 or 27; 1 : 4000;
a kind gift from Dr Thomas Jenuwein, Max-Planck-Institute
of Immunobiology, Freiburg, Germany), anti-a-actin (1 : 2500;
no. A2066, Sigma), and anti-hsp90 (1 : 2000; no. sc-7947, Santa
Cruz Biotechnology). Determination of the relative optical
density and quantification of band intensities were performed
using the Kodak Image Analysis Software.
DNMT Activity Assay
Nuclear extracts from cortical astrocytes were obtained
using the EpiQuik Nuclear Extraction Kit (Epigentek,
Brooklyn, NY) according to the manufacturer’s instruc-
tions. DNMT activity was determined by incubating 4mg
of protein nuclear extract with 0.5 mg Poly (deoxyinosinic-
deoxycytidylic) acid (Poly(dI-dC) Poly(dI-dC); Sigma) in
reaction buffer (20mM Tris pH 7.8, 10% glycerol, 5mM
EDTA, 1mM DTT, 0.2mM PMSF) containing 3mM
S-adenosyl-L-[methyl-3H]methionine (3H-SAM, specific activ-
ity: 15Ci/mmol; GE Healthcare, Munich, Germany) for 3h at
371C. Thereafter, DNA was isolated using the GeneClean Kit
(MP Biomedicals). To reduce background signals, three
washing steps were conducted and the DNA binding step
was performed in the presence of a 1000 times excess
of unlabeled SAM to reduce nonspecific binding of the
labeled SAM. To minimize the loss of DNA, genomic DNA
(3 mg per sample) was added to the binding buffer.
Isolation of Genomic DNA
Isolation of genomic DNA was carried out by salting out pro-
teins and precipitating the genomic DNA with isopropanol
as described previously (Zschocke et al, 2007).
Luminometric Methylation Analysis
Luminometric methylation analysis (LUMA) was performed
according to Karimi et al (2006), with minor modifications.
Briefly, 2mg of genomic DNA was cleaved with 4Units of
Eco RI (Fermentas, St Leon-Rot, Germany) in a buffer con-
taining 66mM Tris-acetate, 20mM Mg-acetate, 0.2mg/ml
BSA, 132mM K-acetate pH 7.9, for 2 h at 371C. Eco RI was
inactivated at 651C for 20min. Subsequently, the reaction
content was diluted by adding an equal amount of dH2O.
In two separate 20 ml reactions, DNA (1 mg each) was
subjected to enzymatic digestion by adding 2Units of Hpa
II or Msp I (New England Biolabs, Frankfurt, Germany),
and the mixture was incubated 4 h at 371C. After heat
inactivation of Hpa II and Msp I at 651C for 20min, samples
were processed using a pyrosequencer (Biotage, Uppsala,
Sweden). The Hpa II/Eco RI and Msp I/Eco RI ratios were
calculated, and the result of the measurement was expressed
as the percentage of CCpGG methylation.
Methylation Analysis by Bisulfite Genomic Sequencing
Bisulfite treatment of genomic DNA (2 mg) was performed
using the EpiTech Bisulfite Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Bisulfite-
specific primers were designed using Methyl Primer Express
Software (Applied Biosystems). The PCR mixture was
composed of 1 PCR Buffer (Invitrogen), 1.5mM MgCl2
(Invitrogen), 0.2mM of each dNTP (peqLAB, Erlangen,
Germany), 0.5–1 mM of each primer, and 4Units of DNA
Taq polymerase (Invitrogen). Sequences of primers are
listed in Table 1. Methylation of individual CpG sites was
detected by direct sequencing (Qiagen). All sequencing
reaction mixtures were based on the BigDye 3.1 Terminator
chemistry (Applied Biosystems). Data collection was carried
out on a 3730 l DNA Analyzer (Applied Biosystems).
Quantitative Real-Time RT-PCR
Total RNA was prepared from astroglial cells according to
the manufacturer’s protocol for NucleoSpin RNA II
(Macherey-Nagel, Du¨ren, Germany). A total of 500 ng of
purified RNA was transcribed with random primers and
Table 1 Primer Sequences Used for Bisulfite Sequencing (bs), Quantitative Real-Time PCR (qPCR) and Chromatin Immunoprecipitation (ChIP)
Primer Primer pair sequences TA (1C) GenBank access. no.
GLT-1 CpG island (bs) fwd 50-GGGGTTAAATTTTGTAATTTTT-30
rev 50-CCCCTCCTAAATAAACCCTT-30
52 AY643513
GLT-1 prox. promoter region (bs) fwd 50-TTAGATGTTTAGGGAGTGATGG-30
rev 50-CTATCCCTCTTCTATTATCCCTC-30
63 EF017228
GLT-1 dist. promoter region (bs) fwd 50-ATTGGTAGGTAAATAAAAAATAAATTT-30
rev 50-ATTCAAAAACTATACTATCAAACTCC-30
56 EF017228
LINE-1 (bs) fwd 50-TTAGTTTGAAGAGGTTGTTATTG-30
rev 50-TCCTATCAACCCTACACTCTAA-30
61 M60824
Lambda DNA (bs) fwd 50-GTTGGATGTAGAAAGTTGGAAG-30
rev 50-TTTATCATACAACCCTATCTCCC-30
56 J02459
GLT-1 (qPCR) fwd 50-CCGAGCTGGACACCATTGA-30
rev 50-CGGACTGCGTCTTGGTCAT-30
60 X67857
Actin (qPCR) fwd 50-CTACAATGAGCTGCGTGTGGC-30
rev 50-CAGGTCCAGACGCAGGATGGC-30
60 BC063166
GLT-1 dist. promoter region (ChIP) fwd 50-TTCGGTCTCTGAAGCATGTG-30
rev 50-TAGCCCAAAGGCACTCTCAT-30
60 EF017228
Annealing temperatures of the corresponding primer pairs and GenBank accession numbers are provided.
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Omniscript Reverse Transcriptase (Qiagen). Quantitative
real-time PCR analysis of GLT-1 cDNA was performed
using the LightCycler Carousel-Based System (Roche
Applied Science, Mannheim, Germany) and SYBR green
(QantiFast SYBR Green, Qiagen). b-Actin was used as an
endogenous control for normalization. The primers used
are listed in Table 1. Relative changes of gene expression
were calculated using the comparative DDCT method.
Transient Transfection and Luciferase Reporter Assay
Approximately 35 106 primary cortical rat astrocytes
were transiently transfected with human EAAT2 promoter
reporter plasmid (a kind gift from Dr Ju¨rgen Engele,
University of Leipzig, Leipzig, Germany) using Amaxa’s
Nucleofector device (Amaxa Biosystem, Cologne, Germany).
Simian virus 40 promoter-driven nonsecretory Gaussia
luciferase expression vector was cotransfected to correct
for transfection efficiency. Twenty-four hours after trans-
fection, drug treatment was carried out for 24 h. Luciferase
assays were performed by applying the Dual Luciferase
Assay System (Promega, Mannheim, Germany) using the
TriStar LB941 Luminometer (Berthold Technologies, Wild-
bad, Germany).
Chromatin Immunoprecipitation
After pharmacological treatment, 2 106 astrocytes were
fixed in vivo with 1% formaldehyde for 10min, and the
reaction was finally quenched with 0.125M glycine for 5min
at RT. From then on, all steps were carried out at 41C, if not
stated otherwise. Nuclei were extracted in 1ml hypotonic
buffer composed of 0.5% Igepal-CA630, 10mM KCl, 1.5mM
MgCl2, and 10mM HEPES, pH 7.9, followed by 15min of
incubation on ice and brief homogenization. Nuclei were
recovered by 5min by centrifugation at 800 g. Nuclear
pellets were dissolved in 400 ml lysis buffer (containing 1%
SDS, 10mM EDTA, 50mM Tris-HCl, pH 8.1) and sonicated
using a Branson sonifier (12 20 s bursts, 90% pulse,
output control 4). The average length of DNA fragments
generated by sonication was 500 bp. Two 200 ml aliquots (for
IgG control and 2mg of anti-acetyl-H4 antibody) were 1 : 10
diluted in ChIP dilution buffer (0.01% SDS, 1.1% Triton,
1.2mM EDTA, 167mM NaCl, and 16.7mM Tris-HCl, pH
8.1) and precleared for 3 h with blocked Dynabeads
(Promega, protein A coupled, blocked with 0.1% BSA and
0.05% salmon sperm DNA). Anti-acetyl-H4 antibody was
added to the samples, preincubated for another 2 h, and
rotated overnight with blocked Dynabeads. Four subse-
quent washing steps were carried out using low salt (0.1%
SDS, 1% Triton, 2mM EDTA, 150mM NaCl, 20mM Tris-
HCl, pH 8.1), high salt (see low salt, except 500mM NaCl),
LiCl (0.25M LiCl, 1% NP-40, 1% deoxy-cholate, 1mM
EDTA, 10mM Tris-HCl, ph 8.1), and TE buffer. Elution and
reversion of cross-links were performed in buffer contain-
ing 1% SDS, 50mM NaHCO3, 1mM EDTA, 50mM Tris-HCl
pH 8.0, for 2 h at 621C and a final 951C heating step for
5min. DNA was purified using the ultra-clean PCR Clean-
up Kit according to the manufacturer’s instructions (MoBio
Laboratories, Carlsbad, CA, USA), and later on used in real-
time PCR using primers listed in Table 1.
RESULTS
VPA, but not Other Psychoactive Drugs, Induce Global
Histone Hyperacetylation
In this study, we set out to explore the effects of different
classes of antidepressants (such as VEN, CIT, AMI) and
mood stabilizers (such as VPA, LTG, CBZ) on the epigenetic
machinery of primary rat astrocytes, which express the
classical targets of antidepressants such as serotonin and
noradrenaline transporters, and different 5 HT-receptor
subtypes (Azmitia, 2001; Inazu et al, 2001; Inazu et al,
2003). To further evaluate mechanistic aspects, we also
included the established HDAC-I TSA and NaB in some
assays.
First, we measured the degree of global histone H3 and
H4 acetylation (AcH3, AcH4), which is indicative of cellular
HAT and HDAC activity, after 24 h of drug exposure at two
different concentrations. The lower concentrations are in
the range of therapeutic plasma levels, whereas higher
concentrations represent a value that might be reached in
the brain assuming cumulative processes and enrichment of
the drugs at the loci of action. In addition, TSA was used as
a pan-inhibitor of HDACs. Western blot analysis showed
that out of all psychoactive drugs, only VPA induced
hyperacetylation of both histones H3/H4 in a dose-
dependent manner (Figure 1). Moreover, there was no
profound difference in the pattern of induction when
comparing astrocytes from the hippocampus and cortex.
Dynamic Changes of Histone Hyperacetylation After
VPA Exposure
To evaluate the dynamics of VPA-mediated histone
acetylation during and after drug exposure, we conducted
a time-course analysis of 24 and 72 h VPA treatment,
followed by a drug-removal step for 48 h. In both, cortical
and hippocampal astrocytes, VPA-induced hyperacetylation
of H3K9 was stronger after 24 h than after 72 h, whereas this
difference was less pronounced in the case of H4 acetylation
(Figure 2). A similar trend was observed in cells treated with
0.2 mM TSA. Forty-eight hours after VPA withdrawal,
AcH3K9 and AcH4 returned to basal levels. Our results
indicate that the effects of VPA on histone acetylation are
only transient, peak during the first hours of treatment, and
are fully reversible after drug removal.
DNA Demethylation at CCpGG Sites Exerted by VPA is
Reversible
Histone acetylation and DNA methylation operate in a
concerted manner. In agreement with this hypothesis,
HDAC-Is are capable of inducing DNA demethylation in
human cancer cell lines (Detich et al, 2003; Ou et al, 2007)
and in vivo (Dong et al, 2007). Therefore, we examined
whether VPA/TSA trigger CpG demethylating in nontrans-
formed primary astrocytes. In total, three different methods
were used to determine the degree of global CpG methyla-
tion. LUMA measures the average methylation status of all
CCpGG sites by Hpa II/Msp I restriction analysis, coupled to
a Taq polymerase-dependent luminometric reaction. The
second, capillary electrophoresis technique depicts the
average methylation status of all cytosines. Third, we
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analyzed long interspersed nuclear elements (LINE-1),
serving as surrogate markers of global DNA methylation
changes (Yang et al, 2004), by applying direct bisulfite
sequencing of a certain stretch of the LINE-1 ORFII.
First, we validated the accuracy of LUMA and bisulfite
sequencing with respect to CpG methylation. There was a
high degree of similarity between results obtained by LUMA
and direct bisulfite sequencing (r2¼ 0.98, Supplementary
Figure S1a).
As determined by LUMA, untreated cortical and hippo-
campal astrocytes displayed 64±1% and 67±1% methyla-
tion of CCpGG sites, respectively (Supplementary Figure
S1b). In cells from the cortex, treatment with 1mM VPA
induced significant demethylation after 72 h (4.9±1.8%),
whereas 48 h after drug withdrawal, the level of CCpGG
methylation returned to baseline (Table 2). At a concentra-
tion of 10mM, VPA triggered DNA demethylation by
7.5±1.3% already after 24 h, and reached 17.2±2.0%
after 72 h. Again, demethylation was reversed after 48 h of
drug washout. In cells from the hippocampus, results
obtained by LUMA were slightly less coherent. After 24 and
72 h of 1mM VPA exposure, significant hypomethylation
(9.7±2.4% and 5.2±0.6%, respectively) was observed.
Higher doses of VPA of 10mM induced 5.0±1.4%
hypomethylation after 72 h. Although the reversibility of
methylation changes was not as pronounced as in the
cortex, it appeared to be in this direction. Finally, 0.2 mM
TSA induced significant DNA hypomethylation at CCpGG
sites in the cortex and hippocampus. Collectively, our
results suggest that VPA-induced hypomethylation of
CCpGG profiles are present in both brain regions, although
magnitude and kinetics seem to differ slightly.
DNA demethylation processes can occur passively by eg,
retention of DNMT enzymes in the cytoplasm during cell-
cycle transitions. In addition, active mechanisms of DNA
demethylation occurring in quiescent cells in short periods
of time are discussed, requiring a putative demethylating
enzyme or DNA repair machinery. To determine the
percentage of cells present in different stages of the cell
cycle, we conducted flow cytometry analysis (Supplemen-
tary Figure S2). Prolonged treatment with 10mM VPA for
72 h increased the percentage of G1/G0 cells by 9% (92±1%
of the total cells), paralleled by a reduction of cells in the
S- and G2/M-phase (2±1% and 6±1% of the total cells,
respectively). The cell-cycle data illustrate that very few
of the untreated astrocytes were in the S-phase and VPA
reduced this number even further. Thus, it seems very
unlikely that the VPA-mediated reduction in DNA methyla-
tion by 18% (LUMA) can be accounted for by the few
dividing cells. Thus, VPA might rather trigger active
demethylation processes as already claimed by other groups
for eg, HEK293 cells (Detich et al, 2003).
Figure 1 Screen of psychoactive drugs for their global effects on histone acetylation. Cortical (CTX; a, b) and hippocampal astrocytes (HPC; c, d) were
treated with VPA (1 and 10mM), LTG (10 and 100 mM), CBZ (10 and 100 mM), VEN (1 and 10mM), CIT (1 and 10 mM), AMI (1 and 10mM), or with the
HDAC inhibitor TSA (0.2 mM) for 24 h. After drug treatment, cell lysates were prepared and subjected to western blot analysis using polyclonal antibodies
against AcH3K9 and AcH4. AcH3K9 and AcH4 band intensities were normalized to a-actin. The bars are depicted as the percentage of optical band
densities (mean±SE, n¼ 2) calculated relative to the value that corresponds to histone acetylation induced by TSA (set to 100%); t-test: *po0.05 vs
untreated cells, **po0.005 vs untreated cells.
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Figure 2 VPA induces dynamic changes of AcH3K9 and AcH4 patterns in astrocytes from different brain regions. Cortical (a, b) and hippocampal (c, d)
astrocytes were exposed to 1 and 10mM VPA for 24, 72, and 72 h, followed by a 48 h washout period, whereas a single dose of TSA (0.2mM) was applied
for 24 and 72 h. The level of AcH3K9 and AcH4 was monitored by western blot analysis and detected with AcH3K9- and AcH4-specific antibodies. a-Actin
immunoreactivity served as a control for protein loading. Optical densities of AcH3K9- and AcH4-specific bands were normalized to a-actin. Data represent
mean±SE (n¼ 2) of the percentage of optical band densities calculated relative to the value that corresponds to histone acetylation induced by 24 h
treatment with 0.2mM TSA (set to 100%); t-test: *po0.05 vs untreated cells, **po0.005 vs untreated cells, #po0.05 vs 1mM VPA depletion treatment,
}po0.05 vs 10mM VPA depletion treatment.
Table 2 VPA/TSA and AMI Trigger CCpGG DNA Hypomethylation
Treatment
Change in DNA methylation analyzed by LUMA
Drug 24h 72h 72h+48h washout
CTX HPC CTX HPC CTX HPC
1mM VPA 4.2±3.3 9.7±2.4* 4.9±1.8* 5.2±0.6* 0.6±2.8 6.7±2.4
10mM VPA 7.5±1.3* 4.0±2.7 17.2±2.0* 5.0±1.4* 2.6±4.1 6.0±3.1
100mM LTG n.d. n.d. +0.5±3.0 n.d. n.d. n.d.
1 mM AMI 7.4±4.2* n.d. 9.7±4.0* n.d. 4.4±1.3 n.d.
10 mM AMI 4.3±2.8 n.d. 9.2±2.0* n.d. 6.5±3.5 n.d.
0.2 mM TSA 7.1±3.7* 9.6±1.0* 11.6±5.0* 10.4±2.3* n.d. n.d.
Abbreviation: n.d., not determined.
Primary astrocytes were treated with different concentrations of VPA, LTG, AMI, and TSA as specified in the table. Levels of DNA methylation were measured
after 24 and 72 h, as well as after the washout period. For all experiments, genomic DNA was isolated from the cells and 2 mg was subjected to luminometric
methylation analysis (LUMA). The results are expressed as mean±SE of the percentage of the change in CCpGG DNA methylation compared with untreated cells.
The experiments were performed in two to four independent trials, each with six technical replicates; t-test: *po0.05 vs untreated cells.
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Amitriptylin Induces Genome-Wide CCpGG
Hypomethylation Independent of HDAC Inhibition
We further examined whether drugs that do not possess
HDAC inhibitory activities might also alter the degree of
DNA methylation. For that purpose, we chose AMI from the
group of antidepressants, and LTG as a mood stabilizer, and
treated cortical astrocytes with 100 mM LTG for 72 h and
with 1 or 10 mM AMI (for 24 and 72 h). Surprisingly, AMI
(1 mM) exposure led to a significant decrease of methylation
at CCpGG sites after 24 and 72 h (7.4±4.2% and
9.7±4.0%, respectively) (Table 2). A higher dose was
also effective after 72 h of the treatment (9.2±2.0%). In
contrast, LTG exposure did not produce changes of DNA
methylation. Thus, AMI induced significant DNA hypo-
methylation (Table 2) in the absence of global histone
hyperacetylation (Figure 1), which was partially reversible
after drug withdrawal.
Total Cytosine Methylation is not Altered by Drug
Exposure
Of all CpG sites in the genome, CCpGG tetranucleotides
represent only a minor part of approximately 7–8%, where
35.25% of these sites are located in transposable elements,
64% in unique sequences, from which 14% are in CpG
islands, as calculated for the mouse genome (Fazzari and
Greally, 2004). As LUMA exclusively detects CCpGG sites,
we additionally performed capillary electrophoresis analysis
covering the methylation status of all CpG sites. The
equivalent LUMA samples of (1) the time course of high
dose VPA and (2) the 72 h time point of high dose AMI were
subjected to capillary electrophoresis analysis. Strikingly,
differences in total cytosine methylation levels between
control and treated astrocytes could not be detected by
capillary electrophoresis (Supplementary Table 1). Possibly,
smaller changes in cytosine methylation that might not be
evenly distributed over the whole genome, but rather
located at certain CCpGG-rich DNA regions, could be
better resolved by LUMA than by the capillary electrophor-
esis technique.
Finally, genomic DNA derived from cortical astrocytes
treated with VPA (10mM), TSA (0.2 mM), AMI (10 mM), and
LTG (100 mM) for 72 h showed no differences in the average
methylation levels of total LINE-1 CpGs sites compared with
control cells (Supplementary Figure S3a-c). Together with
the results obtained from capillary electrophoresis and
LUMA analysis, we propose that VPA, TSA, and AMI do not
cause ample DNA hypomethylation randomly at any CpG
site of the genome, but rather at distinct regions that are
likely enriched in CCpGG tetranucleotides and prone to
DNA demethylating events.
Modulation of the Epigenetic Signature of an
Astrocyte-Specific Promoter by VPA and TSA
On the basis of our observations that VPA triggers global
histone hyperacetylation and DNA hypomethylation events,
and that AMI, to a certain extent, influences the genomic
DNA methylation status as well, we speculated whether
genes crucial for the physiology of astrocytes are among the
affected loci. As a paradigm, we chose the glutamate
transporter subtype, GLT-1 (EAAT2, human homolog),
the gene product ensuring low resting glutamate concentra-
tions in the synaptic cleft (Choi, 1988; Rothstein et al, 1996).
Previously, we collected data of an epigenetic component of
human EAAT2 regulation (Zschocke et al, 2007), and there
is increasing evidence that a disturbed glutamatergic
neurotransmission in psychiatric disorders might also be
affected by pharmacological interventions (Hashimoto et al,
2007; Javitt, 2004).
Hence, we determined the methylation status of the rat
GLT-1 gene covering a substantial part of the 50-UTR and
two parts of distinct promoter regions by bisulfite sequen-
cing. The 50-UTR of GLT-1 is composed of a classical CpG
island (Zschocke et al, 2005). Sequencing of approximately
two-thirds of the CpG island (Figure 3a) showed that all
inspected CpG dinucleotides were unmethylated in un-
treated cortical astrocytes. Furthermore, a region outside
the CpG island located B900 bp upstream of the ATG start
codon was also completely unmethylated (data not shown).
Nevertheless, a region B1950 bp relative to the ATG start
codon that contains putative binding sites for two
chromatin-associated transcriptional regulators, proofed
to be differentially methylated before and after drug
exposure. Three CpG sites at positions 1978, 1958, and
1929 were methylated to 34±1%, 33±1%, and 36±2%,
respectively, in untreated cells, as measured by direct
bisulfite sequencing (data not shown). A 72 h treatment with
10mM VPA led to a reduction of methylation at all three
sites (18.3±7.8%, 16.8±0.3%, and 27.7±4.6%, re-
spectively) (Figure 3b). Similarly, TSA noticeably decreased
cytosine methylation by 27.7 to 32.5%. In contrast to
VPA/TSA, AMI (10 mM, 72 h) did not induce significant
changes at any of the examined CpG dinucleotides.
Similarly, LTG (100 mM, 72 h) did not change the methyla-
tion at positions 1978 and 1958, although a small
increase in cytosine methylation was detected at position
1929 ( + 9.2±1.8%). Our findings show that global
CCpGG DNA hypomethylation induced by VPA, TSA, and
AMI have differential impacts at the single gene level.
To further characterize the epigenetic signature at the
GLT-1 promoter after drug exposure, we investigated the
composition of acetylated histone H4 at the differentially
methylated promoter stretch by chromatin immunopreci-
pitation (ChIP). Indeed, we observed a 3.5-fold enrichment
of acetylated H4 at the GLT-1 promoter in VPA (10mM,
72 h) treated cortical astrocytes, as compared with control
cells (Figure 3c).
HDAC-Is Increase GLT-1 Gene Transcription in Cortical
Astrocytes
As VPA and TSA treatment resulted in an altered epi-
genetic composition of the GLT-1 promoter that potentially
leads to a more relaxed chromatin structure, we tested
whether these compounds are able to enhance GLT-1
mRNA transcription. In untreated cortical astrocytes,
GLT-1 mRNA was detected at fairly moderate levels as
determined by real-time PCR. After stimulation with VPA
(low millimolar range) or TSA (low nanomolar range) for
24 h, we observed a dose dependent B4-fold increase of
GLT-1 mRNA, respectively (Figure 4a and b). Moreover,
neither AMI nor LTG influenced GLT-1 mRNA expression
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(data not shown). A reporter gene assay with the human
GLT-1 promoter ortholog coupled to a luciferase gene
confirmed the activation of the promoter by VPA and
TSA, but not by LTG or AMI treatment (Figure 4c). This
alludes to a role of transacting factors that might be
triggered by VPA/TSA, as chromatin modifications at
the reporter plasmids might be less relevant. We further
tested whether the HDAC-I NaB also exerts an effect
on GLT-1 expression in cortical astrocytes. Application
of 1mM NaB increased GLT-1 mRNA transcript levels
after 72 h, but not at 24 h of treatment as determined by
real-time PCR analysis (Figure 4d). Compared with VPA
and TSA, this regulatory effect was weaker with regard
to the kinetics of gene activation. In conclusion, CpG
demethylation and histone hyperacetylation of a distinct
region of the GLT-1 promoter induced by VPA or TSA was
associated with an increased transcriptional activity of
the gene. Conversely, AMI and LTG, failing to modify
epigenetic marks at the promoter, did not enhance the
basal transcription of GLT-1.
Figure 3 Epigenetic modification of the GLT-1 promoter of rat cortical astrocytes by VPA and TSA treatment. (a) The scheme depicts the 50-UTR
of GLT-1 and adjacent promoter region. Empty circles represent unmethylated CpG regions, whereas filled circles represent moderately methylated
individual CpGs (B34%), as measured in untreated cortical astrocytes. The genomic sequence of GLT-1 distal promoter region is shown and putative
binding sites for myb-like transcriptional regulator (myb TR) and for nuclear factor-1 (NF-1) are depicted. (b) CpG methylation changes were monitored
at individual CpG sites (1978, 1958, and 1929) after drug exposure. Cortical astrocytes were treated for 72 h with 10mM VPA, 0.2 mM TSA,
10 mM AMI, and 100 mM LTG. After treatment, genomic DNA was isolated, bisulfite-converted, PCR amplified, and submitted to direct sequencing.
Bars represent percentage change of CpG methylation (mean±SE, n¼ 3) compared with untreated cells; t-test: *po0.05 vs control, **po0.005 vs
control, ***po0.0005 vs control. (c) Cortical astrocytes were exposed to 10mM VPA for 72 h, genomic DNA was isolated, fragmented and
immunoprecipitated using an anti-AcH4 antibody or IgG control. Precipitated DNA was subjected to real-time PCR analysis with a GLT-1 promoter-specific
set of primers. AcH4 enrichment is depicted as fold-increase±SE (n¼ 2) compared with untreated cells (set to 1). The results are normalized to input;
t-test: ***po0.0005 vs control.
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Cellular DNMT-1 and GADD 45a Protein Levels are
Unaffected by VPA/TSA and AMI
The molecular mechanisms of DNA demethylation are still
unclear. We focused our further analysis on two key factors
that are responsible for propagation, maintenance, or de
novo establishment of DNA methylation patterns, namely
DNMT-1 and GADD 45a (growth arrest and DNA damage-
inducible protein 45a). In cortical astroglial cells, treatment
with 1 and 10mM VPA or with 200 nM TSA for 24 and 72 h,
did not significantly decrease the levels of DNMT-1 protein
under either condition (Figure 5a). In addition, AMI did not
influence DNMT-1 levels under the specified treatment
regiment (Figure 5b). Recently, it has been proposed that
GADD 45a might have an active role in demethylating DNA
(Barreto et al, 2007). As shown in Figure 5a and b, VPA/TSA
and AMI did not robustly alter GADD 45a expression levels,
although TSA slightly reduced protein levels after prolonged
exposure. Our data imply that global changes in DNA
methylation are not correlated with major differences in
DNMT-1 or GADD 45a protein levels after VPA/TSA and
AMI administration.
DNMT Activity is Differentially Affected by VPA
and AMI
To test the possibility that DNMT activity is directly
modified by VPA or AMI, we performed an in vitro
methylation assay using poly dIdC DNA as template and
tritium-labeled S-adenosyl-methionine (3H-SAM) as sub-
strate. Nuclear extracts of VPA (10mM, 72 h)- and AMI
(1, 10 mM; 72 h)-treated cortical astrocytes were subjected
to methylation reaction, and the amount of incorporated
3H-SAM was quantified (Figure 5c). In parallel, aliquots of
nuclear extracts were analyzed for DNMT-1 levels by
western blot (data not shown). VPA did not reduce the
amount of incorporated SAM, nor were nuclear DNMT
protein levels significantly reduced in the nuclear extracts,
indicating that VPA does not impair DNMT function.
Conversely, 10 mM AMI led to a dramatic reduction in
DNMT enzymatic activity of B55% (Figure 5c), concomi-
tantly with unchanged DNMT-1 levels (data not shown).
Application of the specific DNMT inhibitor 5-aza-deoxycy-
tidine (8mM; 3–11 days) reduced the activity of DNMT by
approximately 50–90%, which proofs the reliability of the
Figure 4 HDAC inhibitors VPA and TSA increase GLT-1 gene transcription in a dose-dependent manner. GLT-1 transcript levels were quantified
by real-time PCR after 24 h treatment with 2.5, 5, and 10mM VPA (a) and with 5, 15, or 30 nM TSA (b) and 24 and 72 h after 1mM NaB treatment (d).
Real-time PCR analysis was carried out with total RNA derived from treated and untreated (Co) cortical astrocytes and with GLT-1- and actin-specific
primers. (control is set to 1; bars depict mean±SE (n¼ 3) of the fold-increase; t-test: *po0.05 vs control, **po0.005 vs control.) (c) Reporter gene assays
were conducted to directly assess promoter activity. Cortical primary astrocytes were transiently transfected with reporter plasmid containing a homolog
of the human GLT-1 promoter coupled to a luciferase gene. The cells were cotransfected with nonsecretory Gaussia luciferase expression vector
for normalization. The luciferase activity was assayed 24 h after applying drugs at the indicated concentrations. Bars present mean±SE (n¼ 3–5) of the
fold-increase compared with untreated cells (set to 1); t-test: *po0.05 vs control.
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assay to monitor DNMT activity changes. Altogether, our
results indicate different modes of actions by VPA and AMI
to reduce DNA methylation.
VPA and AMI Differentially Modulate Histone H3K9
Methylation Marks
So far, our results endorsed the idea of differing actions of
VPA and AMI with regard to histone acetylation patterns
and induction of GLT-1 expression. To corroborate these
findings with other putative differences, we focused on
further histone marks, the dimethylation of histone H3 at
lysine residues 9 (2MeH3K9) and 27 (2MeH3K27). Psy-
choactive drugs possess the potential to influence the level
of histone methylation in vivo (Huang et al, 2007; Tsankova
et al, 2006; Wilkinson et al, 2009). We exposed cortical and
hippocampal astrocytes to VPA (1 and 10mM) and AMI (1
and 10 mM) for 24 h, and performed western blot analysis
using 2MeH3K9- and 2MeH3K27-specific antibodies. VPA
slightly, but significantly, decreased the levels of 2MeH3K9,
whereas AMI showed a minor and nonsignificant increase
of this repressive histone mark (Figure 6a and b). The
applied drugs exerted no effect on 2MeH3K27 in both brain
regions (Figure 6c and d). It is noteworthy that although the
slight increase in 2MeH3K9 levels induced by NaB (applied
at 0.1 and 1mM for 24 h) was not significant compared with
controls, these levels were significantly different from the
reduced levels in response to the structurally related drug,
VPA (Figure 6a and b). In this context, it is worth
mentioning that NaB exposure did not result in global
CCpGG methylation changes, although both substances
VPA and NaB increased acetylation of H3 and H4 to a
similar extent (data not shown). Collectively, our data
support the idea that VPA and AMI affect different
chromatin components as reflected at the level of 2MeH3K9
or AcH3/4. Furthermore, also structurally similar HDAC-I
like VPA and NaB do not necessarily match in their
epigenetic modes of action. This is in agreement with other
studies showing various HDAC-I differentially affecting
target genes (Hauke et al, 2009).
DISCUSSION
There is mounting evidence that psychiatric illnesses, major
depression in particular, are associated with compromised
glial function. For example, a reduced number of glial cells
was reported in the prefrontal, orbitofrontal, and cingulate
cortex (Cotter et al, 2001; Rajkowska et al, 1999). A number
of animal studies replicated similar findings, for example,
describing a 25% reduction of glial cells in the hippocampal
formation of psychosocially stressed male tree shrews (Czeh
et al, 2006). It is noteworthy that fluoxetin treatment for 28
days prevented the numerical decrease in astrocytes of the
animals. Hence, abnormal astrocytic function might add to
the pathogenesis and progression of mood disorders by
deteriorating neuroplasticity and related processes. It has
become increasingly evident, that beside neurons being the
primary targets of antidepressant/mood stabilizer action,
astrocytes also respond to these treatments (Manev et al,
2003; Pavone and Cardile, 2003).
In this study, we evaluated the effects of CIT, AMI, VEN,
as well as VPA, LTG, and CBZ on various aspects of
astroglial epigenetic parameters. For mechanistic insight,
we also applied broad-spectrum HDAC-I, including TSA
and NaB. With regard to HDAC subtypes, TSA is generally
considered to inhibit both class I and class II HDACs,
whereas VPA and NaB are preferentially class I inhibitors
(Guardiola and Yao, 2002; Gurvich et al, 2004). Of all
psychoactive drugs tested, only VPA led to a pronounced
and transient global hyperacetylation of histones H3 and
H4, paralleled by a small and transient demethylation of
genomic CCpGG tetranucleotides. These results are con-
sistent with previous studies showing that VPA directly
inhibits the catalytic center of HDAC 2 with an EC50 value of
0.52mM and of HDAC 5/6 with an EC50 of 2.4mM
(Gottlicher et al, 2001). HDAC-Is such as MS-275 and TSA
also diminish DNMT-1, 3a and 3b protein levels and
Figure 5 AMI, but not VPA, reduces DNA methyltransferase activity of
cortical astrocytes independent of DNMT-1 downregulation. (a, b) Drug
treatment has no impact on DNMT-1 and GADD 45a expression levels.
Cortical astroglial cells were treated with VPA, AMI, and TSA ranging from
24 to 72 h, including drug washout as specified. Western blot analysis was
carried out using cellular extracts prepared from cortical astrocytes, which
were probed with DNMT-1-, GADD 45a-, a-actin-, or hsp90-specific
antibodies. (c) Cells were treated with VPA (10mM), AMI (1,10 mM), and
5-Aza (8mM) for 3d or 6–11d (5-Aza, long-term). Nuclear extracts were
isolated and supplemented with the respective drugs. DNA methyltrans-
ferase activity was quantified by measuring the incorporation of S-adenosyl-
L-[methyl-3H]methionine into the substrate Poly(dI-dC)  Poly(dI-dC). Data
are presented as relative DNA methyltransferase activity±SE (n¼ 2 for
VPA/5-Aza, n¼ 4 for AMI). Control is set to 100%.
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enzymatic activity in NT-2 precursor cells, tentatively
explaining the mechanism of DNA demethylation events
(Kundakovic et al, 2009). In primary astrocytes, we found
no changes in DNMT-1 levels upon VPA administration.
GADD 45a, a protein involved in cell-cycle control and DNA
repair, represents a candidate as a mediator for active DNA
demethylation as the overexpression of GADD 45a activates
methylation-silenced reporter plasmids and promotes
global DNA demethylation. VPA upregulates GADD 45a in
N1E-115 neuroblastoma cells, thereby inducing growth
arrest (Yamauchi et al, 2007), whereas in astroglial cells,
GADD 45a levels were not elevated after VPA and TSA
exposure in our experimental setup. Hence, we conclude
that mechanisms other than DNMT-1 downregulation and
GADD 45a upregulation are accountable for VPA-mediated
CCpGG demethylation in quiescent cells. It is noteworthy
that LINE-1 retrotransposons were spared from demethyla-
tion events, and methylation changes were not measurable
at total cytosine residues, possibly due to resolution limits
of capillary electrophoresis. In that context, VPA presum-
ably does not reactivate silenced retrotransposons, which
would harbor a mutagenic risk for the cell, and also does
not mediate the demethylation of the gross of genomic CpG
sites. We further observed small brain region-specific differ-
ences in responsiveness to DNA demethylation triggered by
VPA, with generally lower magnitudes in the hippocampus.
Although it has been shown that CBZ inhibits represen-
tatives of class I and class II HDACs leading to slightly
increased AcH4 levels in human HepG2 and HEK cell lines
(Beutler et al, 2005), CBZ did not exert similar effects in
primary astrocytes. Possibly, cells treated with CBZ need to
actively proliferate to be more susceptible for these minor
acetylation changes, as opposed to VPA. Moreover, LTG
did not mediate any changes in the global histone acetyla-
tion profile in astrocytes. Similarly, acutely administered
antidepressants CIT, AMI, and VEN did not show any
significant influence on the global H3 and H4 acetylation
status in hippocampal and cortical astrocytes. At this point
in time, we cannot exclude the possibility that chronic
administration of the drugs over several weeks might,
nevertheless, change the degree of histone acetylation. Daily
i.p. injections of fluoxetine, a substance related to CIT, over
10 days leads to an increase in HDAC2 immunoreactivity in
coronal tissue sections, accompanied by reduction in global
acetylated histone H3 (Cassel et al, 2006). Furthermore,
chronic, but not acute imipramine treatment of socially
Figure 6 Differential effects of VPA and AMI on H3K9 dimethylation levels. Cortical (CTX) and hippocampal (HPC) astrocytes were treated with VPA
(1 and 10mM), AMI (1 and 10mM) and NaB (0.1 and 1mM) for 24 h. Western blot analysis was performed using antibodies directed against (a, b) dimethyl-
H3K9 (a-2MeH3K9) or (c, d) dimethyl-H3K27 (a-2MeH3K9). As a control for protein loading, a-actin-specific antibody was used. Data represent mean±SE
(n¼ 3) of the percentage of optical band densities normalized to a-actin immunoreactivity. Control is set to 1; t-test: *po0.05.
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stressed animals induces hyperacetylation of H3 at distinct
regions of the BDNF gene potentially mediated by the
downregulation of HDAC5 expression.
Surprisingly, although AMI did not display any HDAC
inhibitory properties, it induced DNA hypomethylation at
CCpGG sites in cortical astrocytes, similarly to VPA. This
observation raised the possibility that DNA hypomethyla-
tion does not depend on histone hyperacetylation. Indeed,
DNMT enzymatic activity was markedly reduced in AMI-
treated astroglial cells from the cortex. To our knowledge,
only very few studies deal with psychoactive drug-induced
changes of the global degree of DNA methylation. For
instance, 3-weeks administration of haloperidol, an anti-
psychotic drug, to rats was documented to result in a small,
but significant reduction in total methyl-cytosine content
(Shimabukuro et al, 2009).
DNA methylation and histone acetylation are comple-
mented by combinatorial monomethylation, dimethylation,
or trimethylation of histones H3/H4 to form a complex
epigenetic code-controlling gene transcription (Lachner and
Jenuwein, 2002). There exists a functional interplay of
enzymes establishing various histone and DNA modifica-
tions. For instance, HDAC and H3K9 HMT G9a are
recruited to chromatin sites together with transcriptional
coactivators (Roopra et al, 2004), and DNMT-1 was
reported to interact with SUV39H1, a histone H3K9
methyltransferase (Fuks et al, 2003). Our data show that
VPA exposure caused a slight but specific reduction in the
levels of dimethyl-H3K9, leaving dimethyl-H3K27 un-
changed. In line with our results, HDAC-I desipeptide
decreases the level of H3K9 methylation and induces DNA
demethylation by reducing G9A and SUV39H1 activity and
DNMT-1 binding, respectively (Wu et al, 2008b). In
contrast to VPA, AMI did not change dimethyl-H3K9 levels.
Global epigenetic alterations caused by VPA hit a selected
gene promoter, the activity of which is crucial for astrocytic
functionality, GLT-1. At glutamatergic synapses, GLTs recycle
released extracellular glutamate back into astrocytes to
terminate postsynaptic and presynaptic receptor activation
(Schousboe and Waagepetersen, 2006; Vandenberg, 1998).
Distinct parts of the GLT-1 promoter were demethylated
and enriched in acetylated histone H4 after VPA treatment,
whereas the CpG island in proximity of the translational start
site was completely unmethylated in treated and untreated
cells. Concomitantly, the activity of the GLT-1 gene was
profoundly increased, analogously to the actions of TSA on
GLT-1 gene transcription, indicating that HDAC inhibitory
properties of VPA are attributable to the documented effects.
The differentially methylated promoter region contains puta-
tive consensus sequences (as predicted by MatInspector
software) for the recruitment of two chromatin regulatory
proteins, namely nuclear factor 1 and myb-like transcrip-
tional regulator (Chikhirzhina et al, 2008; Ko et al, 2008).
A number of epigenetically regulated genes such asmyoD are
differentially methylated at distal enhancer elements, whereas
CpG islands close to transcription start sites are protected
from methylation (Brunk et al, 1996) and, hence, are less
susceptible to epigenetic alterations.
Chronic VPA exposure increases GLT-1 expression in vivo
in the rodent hippocampus (Hassel et al, 2001). In addition,
I-phenylpyridinium-challenged primary astrocytes, simulta-
neously treated with TSA, showed improvement in glutamate
uptake as reported by Wu et al (2008a). Very recently, Allritz
et al (2009) showed stimulatory effects of TSA on GLT-1
mRNA and protein levels in rat astrocytes of various brain
regions. We complement the findings that HDAC-I likely
induces GLT-1 expression in part by chromatin changes at the
promoter region, probably in concert with the induction of
transacting factors. Conversely, AMI neither targeted GLT-1
gene transcription nor the respective CpG sites within the
GLT-1 promoter.
Taken together, we could show for the first time that of all
tested psychoactive substances, VPA exerted the strongest
influence on chromatin remodeling events in astrocytes
involving CpG demethylation and histone modifications,
targeting GLT-1, an astroglial gene important for glutamate
homeostasis in the CNS. Similarly, AMI also brought about
changes in global DNA methylation, possibly by functional
impairment of DNMTs, without targeting the GLT-1 gene
(Figure 7). The underlying molecular mechanisms and
biological conditions including different neural cell types
Figure 7 Proposed model for VPA- and AMI- mediated epigenetic
alterations in astrocytes. VPA and AMI display an input on global DNA
demethylation, although through different mechanisms. As VPA inhibits
HDACs, and AMI impairs DNMT function, the measurable difference in
global epigenetic marks consists of hyperacetylation of histones in the
case of VPA, which are not affected by AMI. Locally, downstream
pathways further diverge as exemplified for the GLT-1 gene. The
biochemical composition of the promoter is markedly altered by VPA
exposure by means of histone hyperacetylation and DNA demethylation,
resulting in an enhanced gene transcription. AMI does not possess similar
features, and subsequently leaves gene activity unaffected. Round circles
represent CpG sites; shading reflects the degree of methylation; oval
circles depict core histones.
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and brain regions of AMI-affected DNMT-1 function are yet
to be determined. It will be interesting to uncover the
common and divergent sites affected by the global
demethylating actions by these two drugs. It also remains
to be seen whether other tricyclic and SNRI/SSRI drugs
show similar effects on the DNA methylation machinery,
and whether these effects might contribute to the recovery
of disturbed neural processes.
In conclusion, a promising new approach for the
pharmacological treatment of psychiatric illnesses could
be based on the reversal of aberrantly established epigenetic
patterns. Two principle strategies could guide to the future
objective: first, pharmacological intervention directly inter-
feres with epigenetic machinery as shown in this study for
VPA and AMI, resulting in overall changes in the epigenetic
pattern of chromatin. In fact, HDAC-I NaB exerts anti-
depressant-like effects (Schroeder et al, 2007) and improves
cognitive performance in mice (Fischer et al, 2007).
Apparently, this strategy holds the risk of reactivating
genes in a false spatial-temporal context. The parameter
ensuring that only a subset of crucial genes are reactivated
might rely on the composition of transcription factors
governing the transcriptome characteristic for a specific cell
type, such as an astrocyte or neuron. The second strategy
comprises the indirect modulation of epigenetic marks
either globally or locally by interfering with neurotransmit-
ter and signal transduction pathways, ultimately resulting in
epigenetically based and permanently changed target gene
expression patterns. In general, identifying novel HDAC-I-
or DNMT-1-regulated genes acting in support of neural
circuits might provide a starting point for the development
of new pharmacological treatment designs.
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Supplementary Materials and Methods 
 
 
Flow cytometry - Cell cycle analysis 
 Flow cytometry was performed with VPA-treated cortical astrocytes. The cells were fixed 
with PBS/0.2% formaldehyde on ice for 30 min, washed with PBS and resuspended in 100 µL 
100% (v/v) ice-cold ethanol. After incubation on ice and subsequent centrifugation, RNAse 
(Sigma) in PBS was added and incubated for 30 min at 37 ºC. Finally, staining with 
propidium iodide (50 µg/mL in PBS; Sigma) was conducted. The stained cells were 
immediately subjected to cell cycle analysis using a Beckman Coulter flow cytometer. 
 
 
Capillary electrophoretic analysis of DNA methylation level 
Global DNA methylation levels were determined by capillary electrophoresis, as 
described (Stach et al., 2003). Briefly, 5 µg of genomic DNA was enzymatically hydrolyzed 
to single nucleotides by using an enzyme mixture consisting of micrococcal nuclease (150 
mU/µl; Sigma) and calf spleen phosphodiesterase (2.5 mU/µl; Calbiochem-Novabiochem, 
Darmstadt, Germany). Subsequently, single nucleotides were labeled with the fluorescent 
marker BODIPY (Molecular Probes, Eugene, OR, USA). Labeled nucleotides were separated 
and analyzed in a Beckman P/ACE MDQ Molecular Characterization System. 
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Fig. S1 
 
Fig. S1. Level of CCpGG DNA methylation in untreated astrocytes. (A) Validation of 
Luminometric Methylation Analysis (LUMA) and direct bisulfite sequencing techniques with respect 
to CpG methylation. M.SssI methylated and fully unmethylated Lambda control DNA were mixed to 
obtain 25% , 50% and 75% methylated Lambda DNA that was subsequently subjected to both 
methods. Applying direct bisulfite sequencing, the degree of CpG methylation of a randomly selected, 
248 bp CpG-rich sequence within lambda DNA was determined. The sequence of the bisulfite-specific 
primer pair is listed in Table 1. For LUMA, lambda DNA was cleaved with two combinations of 
restriction enzymes, either Hpa II + Eco RI or Msp I + Eco RI, and digested DNA samples were 
assayed on a pyro-sequencer. The data points present mean values ± S.E. of three independent LUMA 
measurements against a single measurement of lambda DNA methylation performed by direct 
sequencing. A curve constructed to fit the data points revealed a Pearson's correlation coefficient of 
0.98. (B) LUMA-determined level of CCpGG DNA methylation in untreated cortical and hippocampal 
rat primary astrocytes.  
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Fig. S2. Distribution of cortical astrocytes in different cell cycle stages. Astrocytes from the cortex 
were treated with 10 mM VPA for 24 h and 72 h. The cells were harvested, fixed and then stained with 
PI. The relative abundance of cells at different stages of the cell cycle is shown for untreated and 
VPA-treated cells. Bars present the mean ± S.E. (n=3); t-test: * p<0.05 vs. control, **p<0.005 vs. 
control. Twenty-four hours after treatment with 10 mM VPA, the percentage of cells in G1/G0-phase 
was slightly, but significantly increased (89 ± 2% of the total cells), compared to untreated cells (83 ± 
1% of total cells). At the same time, the percentage of cells in S- and G2/M-phase decreased (3 ± 1% 
and 8 ± 2% of total cells, respectively) compared to control cells (6 ± 1% and 10 ± 1% of the total 
cells, respectively).  
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Fig. S3 
Fig. S3. Methylation of repetitive LINE-1 sequences in cortical astrocytes is not affected by drug 
treatment. (A) Schematic presentation of rat LxRN3 LINE-1 sequence (GeneBank accession number 
M60824). Primers were designed for direct bisulfite sequencing of a 413 bp region in the ORF II of 
LINE-1 containing 9 CpG sites. The annealing sites of primers are indicated by arrow heads. Cells 
were treated with VPA (10 mM), TSA (0.2 µM), AMI (10 µM) or LTG (100 µM) and harvested 72 h 
later. Isolated genomic DNA was bisulfite-converted, PCR amplified and submitted to direct 
sequencing (Qiagen). (B) The graph represents methylation levels of all CpGs of the analyzed 
nucleotide stretch within rat LINE-1 repetitive sequence. Bars present the mean value ± S.E. of the 
average CpG methylation level of all nine analyzed CpGs from two to three independent experiments. 
(C) Representation of the percentage of CpG methylation at each individual CpG site before and after 
drug treatment. Each bar represents the mean value ± S.E. (n=2-3) of the methylation degree at a given 
CpG site; t-test: *p<0.05 vs. control. More detailed analysis of individual CpG sites unveiled minor 
differences existing at CpG #4, CpG #5 and CpG #7 in the range of ± 3% (Fig. S2C). Of note, all the 
analyzed LINE-1 CpGs were not embedded in CCpGG tetranucleotides. 
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Supplementary Table 1 
10 mM VPA 10 µM AMI       Drug  
 
       Unit Co 24 h 72 h 72 h + wo Co 72 h 
5mC/5mC+C 4.1±0.1 4.3±0.1 4.4±0.2 4.0±0.4 4.2±0.2 4.5±0.2 
 
Analysis of cytosine methylation levels in cortical rat astrocytes treated with 10 mM VPA (24 h, 72 h 
and 72 h followed by a 48 h washout period (wo)) and 10 µM AMI (72 h). 5 µg of genomic DNA was 
enzymatically hydrolysed. After hydrolysis, nucleotides were labelled with BODIPY and analysed for 
5-methylcytosine (5mC) genomic content by capillary electrophoresis. The result presents mean ± S.E. 
of the ratio of 5-methyl cytidine to total cytidine of a single experiment done with four to five 
technical replicates.  
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ABSTRACT
Astrocytic lineage commitment and brain region-dependent
specialization of glia are partly ascribed to epigenetic proc-
esses. Clearance of glutamate is an essential task, which
astrocytes assume in a temporal-spatial fashion by distinct
glutamate transporter expression. Glutamate transporter
subtype 1 (GLT-1) is predominant in cortex (CTX), while it
plays an inferior role in cerebellum (CER). Here, we set out
to identify regulatory elements that could account for the dif-
ferences in brain region-speciﬁc activity as well as response
to dexamethasone (DEX) or epigenetic factors. We found a
distal promoter element at the shore of the CpG island
exhibiting enhancer function in response to DEX in reporter
gene assays. This shore region showed slight enrichment
in repressive trimethyl-histone H3 (Lys27) and under-
representation of acetyl-histone H4 (H4ac) marks in DEX
nonresponsive CER astrocytes as determined by chromatin
immunoprecipitation. In addition, CpG sites of the shore
region displayed higher methylation in CER than in CTX
cells. Targeted in vitro methylation of CpG sites within the
shore abrogated the stimulatory effects of DEX. Interest-
ingly, the shore was characterized by a pronounced epige-
netic plasticity in CTX cells since DEX exposure elicited an
increase of H4ac in CTX in comparison to DEX nonrespon-
sive CER. The transcriptional activity of this region was also
affected by histone deacetylase inhibitors in a methylation-
and brain region-dependent manner. Together, our study
highlights the impact of an epigenetically adaptive DNA ele-
ment of the GLT-1 promoter being decisive for brain region-
speciﬁc activity and reactivity. VC 2012 Wiley Periodicals, Inc.
INTRODUCTION
Epigenetic modiﬁcations are implicated in the regula-
tion of mammalian brain development and function, and
are important for the integration of external stimuli in
gene activity (Meaney, 2010). Methylation of cytosines
within CpG dinucleotides of the DNA and posttransla-
tional modiﬁcations of histone proteins are major epige-
netic marks that determine chromatin structure. DNA
methylation either directly interferes with the binding
of transcription factors (Campanero et al., 2000; Igu-
chiariga and Schaffner, 1989) or attracts methyl-CpG
binding proteins, which recruit chromatin modiﬁers to
establish a repressive chromatin structure (Jones et al.,
1998; Nan et al., 1998). DNA methylation involved in
gene regulation typically occurs at CpG-dense DNA
stretches designated as CpG islands (Bird, 1986). Inter-
genic and intragenic CpG sites (Maunakea et al., 2010)
as well as CpGs at island shores (Irizarry et al., 2009)
also exhibit regulatory properties.
Covalent modiﬁcations of histones on the N-terminal
tails and the histone fold domain inﬂuence their interac-
tion with DNA and neighboring nucleosomes. Histone
acetylation is generally associated with gene activation
(Pokholok et al., 2005), whereas histone methylation
affects transcription both positively and negatively
depending on the number and location of attached methyl-
groups (Lachner and Jenuwein, 2002). DNA methylation
and histone modiﬁcations act in concert to establish sus-
tainable epigenetic programs (D’Alessio and Szyf, 2006).
Functional specialization of brain regions goes along
with the establishment of region-speciﬁc gene expression
proﬁles (Letwin et al., 2006). Epigenetic mechanisms
appear crucial in the unfolding and stabilization of these
patterns. Pronounced differences between cerebellum
(CER) and cortex (CTX) have been mapped to CpG sites
of genes relevant for brain function (Ladd-Acosta et al.,
2007). Examples of brain area-speciﬁc epigenetic signa-
tures and corresponding gene activity include the Na1,
K1-ATPase modulator Fxyd1, adenosine A2A receptor,
and glutamate receptors (Banine et al., 2011; Buira et al.,
2010; Stadler et al., 2005). Glutamate transporters termi-
nate glutamatergic signaling by clearing glutamate from
the synaptic cleft. Glutamate transporter subtype 1 (in
rodents: GLT-1) and glutamate aspartate transporter (in
rodents: GLAST) are predominately expressed in astro-
cytes; however, they are also localized in cultured neu-
rons as well as in neurons of the rat brain (Anderson and
Swanson, 2000; Chen et al, 2002; Plachez et al., 2000).
GLT-1 and GLAST are expressed in a brain-region spe-
ciﬁc fashion during development and in the adult (Furuta
et al., 1997). GLT-1 is present early in fetal brain and spi-
nal cord, and its expression progressively increases leav-
ing the CER spared until postnatal day 10. The expres-
sion of GLAST is low prenatally, becomes activated in
CER early postnatally and later on also in the forebrain.
In the adult rat brain, the expression of glutamate
transporters is partitioned between different regions,
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with GLT-1 being dominant in forebrain, brainstem, spi-
nal cord, and GLAST in the CER. Accordingly, both genes
respond differently to stimulatory cues depending on the
spatial-temporal context. For instance, stress hormones
up-regulate GLT-1 expression in primary CTX but not in
CER astrocytes (Zschocke et al., 2005). Previous studies
provided ﬁrst indications for an epigenetic control of
GLT-1 transcription in human glioma cells and rat astro-
cytes (Allritz et al., 2009; Perisic et al., 2010; Yang et al.,
2010; Zschocke et al., 2007).
Here, we addressed the question whether epigenetic
events form the basis for the brain region-speciﬁc
expression and responsiveness of the GLT-1 gene in rat
primary astrocytes from CTX and CER. We aimed at
functionally characterizing promoter elements that show
brain region-speciﬁc differences in epigenetic signatures
and confer DNA methylation-dependent response to the
synthetic stress hormone dexamethasone (DEX).
MATERIALS AND METHODS
Primary Astrocytic Cell Cultures
Enriched astroglial cultures were prepared from postnatal
day 1 rat pups (Sprague-Dawley, Charles River, Germany)
as described (Franke et al., 1998). After the third passage,
cells were maintained in serum-free (MEM/Ham’s F-12, 1:1)
N2-supplemented medium and treated with DEX, valproic
acid (VPA) or trichostatin A (TSA), all from Sigma.
RT and Real-Time PCR
Preparation of total RNA and real-time PCR analysis
were as described (Perisic et al., 2010). For detection of
GLT-1 and b-actin in case of semi-quantitative measure-
ments, cDNA was ampliﬁed with P1 and P2 primers,
respectively (Table 1). Generation of PCR products
by quantitative real-time PCR was performed using P2
and P3 primers (Table 1). Here, relative levels of
gene expression were calculated using the formula
2^ 2 (CtGLT-1 2 CtActin) according to the comparative
DDCT method (Livak and Schmittgen, 2001).
Methylation Analysis by Bisulﬁte
Genomic Sequencing
Extraction of genomic DNA from primary astrocytes
was as described (Perisic et al., 2010). Bisulﬁte treat-
ment of genomic or plasmid DNA was performed using
the EpiTech Bisulﬁte Kit (Qiagen) according to the man-
ufacturer’s instructions. Primer pair P4 was used for
ampliﬁcation of the CpG island of the GLT-1 gene and
primers P5 and P6 for ampliﬁcation of the shore GLT-1
promoter region (Table 1). In addition to direct sequenc-
ing, PCR products were also subcloned using the pGEM-
T Easy Vector System (Promega, Mannheim, Germany),
followed by Sanger sequencing.
Construction of reporter plasmids
A 1.8-kb genomic fragment containing the rat GLT-1
gene promoter sequence (from 22,106 to 2253, relative
to TSS; GenBank: EF017228) was ampliﬁed using P7
primers (Table 1) and inserted into the CpG-free lucifer-
ase-reporter pCpGL-basic vector (Klug and Rehli, 2006),
kind gift from Michael Rehli, Department of Haematol-
ogy and Oncology, University Hospital, Regensburg,
Germany. By using pCpGL-basic vector as well as P8
oligonucleotides (which contain canonical TATA-box
element), a pTATA-Luciferase vector was obtained
(Table 1). Furthermore, P9 primers (Table 1) were used
to amplify the shore region of the GLT-1 gene promoter
which was inserted upstream of the TATA-box to gener-
ate the pTATA-GLT121867/21515 vector. The pCpGL-
CMV/EF1a (pCMV/EF1a) vector (kind gift from Michael
Rehli), which harbors a CpG-free constitutive human
elongation factor 1a (EF1a) promoter driven by a TATA-
box, was used for construction of pEF1a-GLT121867/
21515 (employing P10 primers, Table 1). The identity of
all clones was veriﬁed by sequencing.
In Vitro DNA Methylation of Reporter Plasmids
The respective vector (25–30 lg) was subjected to
in vitro methylation at 37C overnight using 10 units of
CpG SssI DNA methyltransferase in a reaction supple-
mented with 650 lM S-adenosyl methionin (SAM). All
reagents were from NEB. The extent of DNA methyla-
tion was evaluated employing HpaII restriction analysis
or genomic bisulﬁte sequencing showing close to 100%
efﬁciency. Mock controls were without SssI DNA methyl-
transferase or SAM in the reaction mixture.
Sequence-Speciﬁc Methylation
(‘‘Patch Methylation’’)
PCR-ampliﬁed GLT-1 promoter shore region was either
methylated or mock-methylated as described above. The
fragments were ligated into the reporter construct and
gel-puriﬁed. Efﬁciency of the methylation reaction was
conﬁrmed by combined bisulﬁte restriction analysis
(Xiong and Laird, 1997). The methylation status of a sin-
gle CpG site, as an indicator of the methylation of the
whole sequence, was inspected in at least 20 independent
subclones. The percentage of DNA methylation was
between 95 and 100%.
Transient Transfection and
Luciferase Reporter Assay
Primary astrocytes (2 3 106) were transiently trans-
fected with 2 lg of reporter plasmids using Amaxa’s
Nucleofector device (Lonza) according to the manufac-
turer’s protocol. The SV40 promoter-driven nonsecretory
Gaussia luciferase expression vector of 15 ng (Sch€ulke
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et al., 2010) served as control for transfection efﬁciency.
Posttransfection for 24 h, the medium was changed to
N2 supplement-containing medium, and the pharmaco-
logical treatment started. Cells were assayed 48 h post-
transfection. Luciferase assays were as described
(Wochnik et al., 2005). Luminescent readouts were
obtained with a TriStar LB941 Luminometer (Berthold
Technologies, Bad Wildbad, Germany). In Figs. 4 and
5B, normalized reporter activity was expressed as
fold-induction relative to the activity in untreated cells.
In Figs. 5A and 6A,B, the reporter activity is depicted
in arbitrary units of Gaussia-normalized Fireﬂy
luciferase to avoid misleading data presentation due to
differential activities of reporter constructs in untreated
cells.
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) analysis was
as described (Perisic et al., 2010). Antibodies were antia-
cetyl-histone H4 (H4ac) (06-866, Millipore; recognizes H4
acetylation at lysines K5, K8, K12, and K16) and anti-H3
antibodies (kind gift from Prof. T. Jenuwein, Max Planck
Institute for Immunology and Epigenetic, Freiburg, Ger-
many): anti-dimethyl-histone H3 (Lys9) (H3K9me2), anti-
trimethyl-histone H3 (Lys9) (H3K9me3), and anti-tri-
methyl-histone H3 (Lys27) (H3K27me3). Relative DNA
enrichment was quantiﬁed by real-time PCR using P11
and P12 primers for ampliﬁcation of the CpG island and
the shore region of the GLT-1 promoter, respectively.
ChIP-qPCR data are initially calculated as percent input.
Percent input was obtained using the formula 100 3
2^(CtAdjusted input 2 CtEnriched). Adjusted input is the Ct
value corrected for differences in the amount of input and
amount of DNA added into the reaction. The fraction that
bound nonspeciﬁcally to protein G Dynabeads was sub-
tracted. Data are presented as percent input (Fig. 2A,B)
or fold-enrichment of immunoprecipitated DNA relative
to control values (control set to 1; Fig. 2C–E) to minimize
variations in immunoprecipitation efﬁciency between the
experiments.
Statistical analysis
Determination of statistical signiﬁcance of differen-
ces between two data sets was performed using two-
tailed Student’s t-test. We also applied three-factor
analysis of variance with repeated measure design for
the analysis of data obtained in patch methylation
experiments.
RESULTS
Induction of GLT-1 Expression by DEX and
HDAC-I Differs Between CTX and CER Astrocytes
To study the responsiveness of the GLT-1 promoter to
stress hormones and epigenetic factors, we used the syn-
thetic stress hormone DEX as well as the histone deace-
tylase inhibitors (HDAC-I) VPA and TSA as established
inducers of GLT-1 (Allritz et al., 2009; Hassel et al.,
2001; Perisic et al., 2010; Zschocke et al., 2005). Under
basal conditions, the mRNA levels of the GLT-1 gene did
not differ between CTX and CER astrocytes (Fig. 1A).
The amount of GLT-1 mRNA of untreated astrocytes
was relatively low and did not translate into detectable
levels of GLT-1 protein (Western blotting, not shown).
Consistent with our previous observations (Zschocke
et al., 2005), 100 nM DEX induced a marked time-de-
pendent increase of GLT-1 mRNA levels in primary CTX
TABLE 1. Primer Sequences Used for Semiquantitative PCR (sqPCR), Quantitative Real-Time PCR (qPCR), Bisulﬁte Sequencing (BS),
Cloning Procedures, and Chromatin Immunoprecipitation (ChIP)
Primer Application Sequences TA (C)
P1 sqPCR fw 50-GGACACCATTGACTCCCAAC-30 58
re 50-CCTCAACACTGCAGTCAGC-30
P2 sqPCR, qPCR fw 50-CTACAATGAGCTGCGTGTGGC-30 60
re 50-CAGGTCCAGACGCAGGATGGC-30
P3 qPCR fw 50-CCGAGCTGGACACCATTG A-30 60
re 50-CGGACTGCGTCTTGGTCAT-30
P4 BS fw 50-GGGGTTAAATTTTGTAATTTTT-30 52
re 50-CCCCTCCTAAATAAACCCTT-30
P5 BS fw 50-GGAGTTTGATAGTATAGTTTTTGAAT-30 58
re 50-AACAAACTCTACTAAAAAACTTACAAA-30
P6 BS fw 50-ATTGGTAGGTAAATAAAAAATAAATTT-30 56
re 50-ATTCAAAAACTATACTATCAAACTCC-30
P7 Cloning fw 50-CGACTAGTTAGGAGCTGCCAAGAGGGTGC-30 68
re 50-ATATGCATAAGCTTCGTACCACGAGTGGCCGTC-30
P8 Cloning 50-ACGACTAGTGACTCTAGAGGGTATATAAAGCTTAAG-30 /
50-CTTAAGCTTTATATACCCTCTAGAGTCACTAGTCGT-30
P9 Cloning fw 50-ACGACTAGTCGTTGGTTGGCCCTACC-30 62
re 50-CTTAAGCTTTATATACCCTCTAGAGTCCGGGTTCCTCTGAGCAG-30
P10 Cloning fw 50-ACGCTGCAGCGTTGGTTGGCCCTACC-30 68
re 50-CTTACTAGTCGGGTTCCTCTGAGCAG-30
P11 ChIP fw 50-GGGCTAAACCTTGCAATCC-30 60
re 50-GCAGACCCGTACCACGAG-30
P12 ChIP fw 50-CAAAACCAAAAACCAAACCAAACC-30 60
re 50-AGCCAAGAAACACGAGGCAG-30
Experimentally determined optimal annealing temperatures (TA) of the respective primer pairs are provided.
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astrocytes, but not in CER astrocytes (Fig. 1B). Surpris-
ingly, VPA reduced GLT-1 mRNA levels in CER astro-
cytes after 24 h of treatment (Fig. 1C), contrasting the
stimulatory effect in the CTX (Perisic et al., 2010).
Treatment of CER astrocytes with TSA (3–250 nM)
exerted a similar repressive effect on GLT-1 expression
(not shown).
Brain Region-Speciﬁc Abundance of H4ac and
H3K27me3 at the GLT-1 Promoter Before and
After Treatment with DEX or HDAC-I
Based on previous ﬁndings suggesting epigenetic regu-
lation of the GLT-1/EAAT2 gene (Allritz et al., 2009; Peri-
sic et al., 2010; Yang et al., 2010; Zschocke et al., 2005,
2007), we screened for epigenetic factors causing the dif-
ferential DEX/VPA responsiveness in astrocytes from CTX
and CER. First, we employed ChIP to decipher the compo-
sition of the following histone marks at the 50-ﬂanking
region of the GLT-1 gene: acetylated histone H4 (H4ac) as
well as methylated histones H3K9me2, H3K9me3, and
H3K27me3. We investigated the CpG island as well as
the shore region. CTX astrocytes accumulated more H4ac
at both the shore and island region than CER astrocytes
(Fig. 2A). In contrast, the level of H3K27me3 was higher
in CER than in CTX astrocytes at the GLT-1 promoter
(Fig. 2B). The histone marks H3K9me2 and H3K9me3
could not be detected at these regions (not shown). This
was not due to antibody inefﬁciency, because
anti-H3K9me2 and anti-H3K9me3 antibodies captured
substantially higher amounts of DNA at the muscle creat-
inine kinase enhancer element (Tao et al., 2011) as com-
pared with the control without antibody (not shown).
Since DEX and VPA differentially regulate GLT-1
gene transcription in CTX and CER astrocytes, we
tested whether this is also reﬂected by concomitant
alterations in H4ac association with the investigated
DNA regions. Exposure to 100 nM DEX induced an
increase of the level of H4ac at the CpG island as well
as at the shore region in CTX (Fig. 2C), but not in CER
cells (Fig. 2D). Previously, we already demonstrated a
similar effect of VPA at this particular region in CTX
cells (Perisic et al., 2010). Intriguingly, in CER astro-
cytes, 5 mM VPA increased the amount of H4ac at both
investigated promoter regions after 24 h (Fig. 2E), de-
spite its repressive effect on gene transcription.
CpG Island Shore Methylation at the GLT-1
Promoter is Higher in CER Than
in CTX Astrocytes
To test whether DNA methylation proﬁles correlate
with brain region-speciﬁc regulation of the GLT-1 gene,
we subjected the CpG island and the shore region of the
GLT-1 promoter to bisulﬁte sequencing (Fig. 3A). All
inspected CpGs of the island (from 232 to 2398) were
unmethylated in both brain regions (not shown). In con-
trast, the CpGs at the shore region (positions 21,867,
21,847, 21,660, 21,643, 21,626, 21,570, and 21,516)
were signiﬁcantly more methylated in CER astrocytes
(Fig. 3B). Treatment of CTX and CER astrocytes with
100 nM DEX or treatment of CER astrocytes with 5 mM
VPA for 72 h did not evoke changes of CpG shore meth-
ylation (not shown). The level of methylation could not
be determined for the CpG dinucleotides at positions
21,750 and 21,714 due to technical difﬁculties in the
sequencing process.
Fig. 1. Expression of the GLT-1 gene under basal conditions and af-
ter DEX or HDAC-I treatment in rat primary astrocytes. A: Compari-
son of basal levels of GLT-1 mRNA in untreated CTX and CER astro-
cytes by quantitative real-time PCR. The GLT-1 transcript level was
normalized to that of b-actin. Relative levels of GLT-1 mRNA are
depicted as mean 1 SE (n 5 3). B: Representative agarose gels show
PCR products of GLT-1 from ampliﬁed cDNA derived from CTX and
CER astrocytes after treatment with 100 nM DEX at the time points
indicated. C: Levels of GLT-1 mRNA in VPA-treated CER astrocytes
were quantiﬁed by real-time PCR. Control (Co) is set to 1 and bars
depict mean 1 SE (n 5 3) of the fold-change of mRNA transcripts rela-
tive to untreated cells.
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Ectopic GLT-1 Promoter is Active in Both CTX
and CER Astrocytes
In addition to chromatin modiﬁcations, brain region
speciﬁc composition of transcription factors might also
contribute to differential gene activity in CTX and CER.
To evaluate whether CER cells contain the necessary
transacting factors for GLT-1 transcription, we tested
the transcriptional activity of an ectopic promoter
sequence (pGLT122106/2253) in CTX and CER astro-
cytes applying luciferase reporter gene assays. In agree-
ment with equal basal transcription of GLT-1, the basal
activity of the reporter gene did not differ between
untreated CTX and CER astrocytes (not shown). After
exposure to DEX or VPA for 24 h, a concentration-
dependent increase in luciferase activity was detected in
astrocytes from both brain regions (Fig. 4A,B). In addi-
tion, we observed a stimulatory effect of TSA on ectopic
GLT-1 promoter activity in both CTX and CER astro-
cytes (not shown). The results of these experiments dem-
onstrate that CER astrocytes also provide transacting
factors required for induction of the GLT-1 promoter
upon DEX treatment, suggesting that the endogenous
chromatin structure is critical for the differential pro-
moter responsiveness between CTX and CER.
DNA Methylation Reduces GLT-1 Promoter
Responsiveness
We next used reporter gene assays to elucidate whether
promoter methylation is involved in GLT-1 gene regulation.
Wemethylated either all CpGs of the full-length GLT-1 pro-
moter or only the CpGs at the shore (positions 21,867,
Fig. 2. Active and repressive histone marks at the promoter region
of the GLT-1 gene in astrocytes. Comparison of H4ac (A) and
H3K27me3 (B) levels at the CpG island and the CpG island shore
region of the GLT-1 promoter in untreated CTX and CER astrocytes by
ChIP analysis (see Fig. 3A for positions of analyzed regions). The occu-
pancy of the H4ac histone mark at the CpG island and shore region
was also determined in CTX cells (Co) before and after exposure to 100
nM DEX (48 h) (C), as well as in CER after treatment either with 100
nM DEX (72 h) (D) or with 5 mM VPA (24 h) (E). Data are presented
as mean 1 SE (n 5 3 2 5, *P < 0.05) of the input percentage or of
enrichment of the DNA bound to histones relative to control (set to 1).
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21,847, 21,818, 21,750, 21,714, and 21660). Mock-meth-
ylated and methylated GLT-1 promoter-driven reporter
plasmids were transiently transfected into CTX astrocytes
and cells were treated with increasing concentrations of
DEX or VPA for 24 h. Methylation of the full-length
pGLT122106/2253 promoter abolished the reporter activ-
ity in both untreated and pharmacologically challenged
astrocytes (Fig. 5A). Selective methylation of the shore
region of the GLT-1 promoter did not change the reporter
activity in untreated cells (not shown) but signiﬁcantly
reduced the stimulatory effects of DEX or VPA (Fig. 5B).
The repressive effect of DNA methylation on the activity of
both GLT-1 promoter-luciferase constructs was also
observed in astrocytes treated with TSA (not shown). These
results point to a methylation-dependent function of the
shore region.
The CpG Island Shore Region of the GLT-1
Promoter Exhibits DNA Methylation-Dependent
Enhancer Function
The concept of an epigenetically controlled enhancer
function of the CpG island shore was further substanti-
ated by the in silico identiﬁcation of several transcrip-
tion factors that putatively bind to this promoter region
in a methylation-dependent manner. Some of them have
been reported to participate in DEX-mediated response
including interferon regulatory factor-1, E-twenty-six
factors, and cAMP response element binding protein
(CREB) (Espinas et al., 1994; Franchimont et al., 2000;
van der Laan et al., 2009). In order to test methylation-
dependent enhancer function experimentally, we cloned
the shore region of the GLT-1 promoter upstream of ei-
ther a TATA-box element or a constitutively active EF1a
element in a CpG-free luciferase reporter vector. Like
the TATA promoter, the EF1a promoter is CpG-free
Fig. 4. Activity of the ectopic GLT-1 promoter in primary astrocytes.
CTX (A) and CER (B) astrocytes were transiently transfected with
equimolar amounts of CpG—free luciferase reporter plasmid containing
a 1.8 kb—long sequence of the rat GLT-1 promoter (pGLT1–2106/–253).
Luciferase activity was assayed 24 h after treatment with the indicated
concentrations of DEX or VPA. Data are presented as mean 1 SE (n 5
9 for CTX; n 5 3 for CER) of the reporter activity in relation to the
activity in untreated cells.
Fig. 3. DNA methylation levels at the GLT-1 promoter in CTX and
CER astrocytes. A: The scheme depicts positions (relative to the tran-
scription start site) and the methylation status of analyzed CpGs at the
GLT-1 promoter. Open circles depict unmethylated, ﬁlled circles methyl-
ated cytosines. B: DNA methylation levels of the CpGs at the shore
region in CTX and CER astrocytes were determined by direct sequenc-
ing of the PCR products, which were obtained from bisulﬁte-converted
DNA. Positions of cytosines at the shore region are also indicated and
given relative to the transcription start site. Data present mean 1 SE
(n 5 3; *P < 0.05, **P < 0.005, ***P < 0.0005) of the percentage of
CpG methylation at individual cytosine residues.
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allowing selective methylation of the shore region of the
GLT-1 promoter. As shown in Fig. 6A, the pTATA-Lucif-
erase vector displayed neither basal nor pharmacologi-
cally induced activity. Addition of the shore region of the
GLT-1 promoter upstream of the TATA-box element sig-
niﬁcantly increased luciferase activity in untreated and
in particular in DEX or VPA exposed cells. Upon methyl-
ation of the CpG dinucleotides at the shore sequence, a
reduction of the drug-induced luciferase activity was
observed. In contrast to the pTATA-Luciferase vector,
the activity of the pEF1a-luciferase vector was increased
by DEX or VPA also in the absence of the shore region
(Fig. 6B). Insertion of the GLT-1 promoter shore
sequence further potentiated the transcription of the
pEF1a vector upon DEX or VPA exposure for 24 h. After
methylation, reporter activity of the pEF1a-GLT1–
1867/–1515 was greatly reduced. Even more, methyla-
tion appears to commute the shore region to a suppres-
sive mode of action under conditions of DEX but not
Fig. 5. CpG methylation inﬂuences GLT-1 promoter activity in re-
porter gene assays. A: Primary CTX astrocytes were transiently trans-
fected with in vitro methylated or mock methylated full length pGLT1–
2106/–253. Luciferase activity was determined 24 h after pharmacologi-
cal treatment for both constructs. Data are presented as mean 1 SE
(n 5 3) of the GLT-1 promoter activity expressed in relative light units
(RLU). B: pGLT1–2106/–253 was methylated only at the distal shore
region (21867/21638) and the activity was compared with its mock
methylated analog in transiently transfected CTX astrocytes. Measure-
ment of luciferase activity was done following the treatment with indi-
cated concentrations of DEX or VPA (24 h). Data analysis was per-
formed using four measurements of each condition and GLT-1 promoter
activity is presented relative to untreated cells (*P < 0.05).
Fig. 6. The shore region of the GLT-1 promoter acts as methylation-
dependent enhancer. Plasmids used in gene reporter assays contain ei-
ther a short sequence with a TATA-box (A) or a constitutively active
EF1a promoter (B). The shore region of the GLT-1 promoter (21867/
21515) was cloned upstream of these sequences. CTX astroglial cells
were transiently transfected with equimolar amounts of plasmids. Lu-
ciferase activity was determined 24 h after pharmacological treatment
(DEX or VPA, with indicated concentrations) for both in vitro methyl-
ated and mock-methylated constructs. Data are presented as mean 1
SE (n 5 4 2 6; *P < 0.05; **P < 0.005) of the GLT-1 promoter activity
expressed in relative light units (RLU).
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VPA exposure. In addition, TSA showed similar effects
to those of VPA (not shown). This set of experiments
suggests that the shore region of the GLT-1 promoter
contains crucial methylation-sensitive cis-active ele-
ments with enhancer function.
DISCUSSION
During mammalian nervous system development, epi-
genetic modiﬁcations of the chromatin play a pivotal
role in the acquisition of the astroglial cell fate
(Freeman, 2010). The molecular switch from neural pro-
genitor cells to astrocytes is accompanied by a marked
reduction of DNA methylation at numerous astrocyte-
speciﬁc gene loci, including glial ﬁbrillary acidic protein
(GFAP) and S100b (Namihira et al., 2004; Takizawa
et al., 2001). In addition to DNA methylation, histone
modiﬁcations at the GFAP promoter are subject to devel-
opmental changes (Song and Ghosh, 2004). Epigenetic
events not only determine basal promoter activity, but
also prepare glial cells for future events by setting the
responsiveness to regulatory inputs. In addition to astro-
cytic lineage commitment, epigenetic factors are thought
to deﬁne the spatial functional specialization of differen-
tiated astroglial cells. Such epigenetic, brain
region-speciﬁc differences presumably exert an impact
on the transcriptome and the molecular response to reg-
ulatory factors as shown here for the GLT-1 gene. While
CER glia fail to up-regulate GLT-1 transcription, CTX
astrocytes showed a strong response to DEX [Fig. 1;
(Zschocke et al., 2005)]. In this study, we provide evi-
dence that the epigenetic signature of the GLT-1 pro-
moter accounts for divergent responsiveness to stress
hormone and HDAC-I in primary astrocytes from two
brain regions, CTX and CER.
The rat GLT-1 gene harbors a canonical CpG island
upstream of the annotated transcription start site
(Zschocke et al., 2005). In CTX and CER astrocytes, the
CpG island was completely unmethylated [Fig. 3;
(Perisic et al., 2010)]. In parallel, the GLT-1 gene was
transcribed at equally low basal levels in astrocytes
from both regions. Most CpG island-associated pro-
moters of housekeeping and tissue-speciﬁc genes are
protected from de novo methylation in untransformed
cells and Sp1 sites seem to play a key role in this pro-
cess (Brandeis et al., 1994). The rat GLT-1 promoter also
contains Sp1 sites within the CpG island (Allritz et al.,
2010) which might, in concert with other cis-active and
transactive elements, account for the absence of methyl-
ation in this region. Nevertheless, the presence of unme-
thylated CpG islands per se is not indicative of an active
or responsive gene. Proximal CpG-dense promoters are
largely free of methylation, whereas CpG-poor promoters
are mostly methylated (Mohn et al., 2008). Distal pro-
moter regions at the shore of CpG islands are also less
CpG-dense, and therefore preferentially targeted by
DNA methylation. Indeed, we detected DNA methyla-
tion at the shore region of the GLT-1 promoter ranging
from 30 to 100% [Fig. 3; (Perisic et al., 2010)]. The
Fig. 7. Model for brain-region speciﬁc expression and responsiveness
of the GLT-1 gene. Chromatin modiﬁcations at the shore and CpG
island of the GLT-1 promoter are depicted comparing CTX and CER
astrocytes. The degree of shading of the lollipops corresponds to the in-
tensity of CpG methylation at the respective sites. Arrows illustrate
transcription start while thickness of arrow heads indicates the level of
transcription. The extent of enrichment of activatory acetylated-H4
(green circles) and inhibitory tri-methylated H3 (red circles) is denoted.
Under basal conditions, the unmethylated CpG island allows leaky
GLT-1 transcription in astrocytes from both brain regions, despite dif-
ferences in histone marks at this region. Upon DEX and HDAC-I expo-
sure, the permissive chromatin structure at the island shore enables
binding of putative transactivator(s) and up-regulation of GLT-1 tran-
scription in CTX astrocytes. This goes along with reshaping the epige-
netic set-up of the promoter, that is, introduction of acetylated H4 as
well as CpG demethylation in case of HDAC-I. In contrast, repressive
chromatin marks or the underrepresentation of activatory marks in
CER glia prevent binding of DEX-induced trans-activator(s) or even
support binding of repressor(s) that mediate HDAC-I-initiated down-
regulation of GLT-1 expression.
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degree of DNA methylation was higher in CER than in
CTX astrocytes. Moreover, this region exerted a strong
enhancer function on reporter gene expression and
proofed to be responsive to stress hormone in depend-
ence of its DNA methylation status. In silico analysis of
the CpG island shore revealed consensus sequences for
a number of transcription factor binding sites function-
ally related to the enhancement of GLT-1 gene activity
such as CREB (Schluter et al., 2002). As demonstrated
in T-cell lineages, most of the differentially methylated
DNA regions are also located at distal promoter sites
and display DNA methylation-dependent enhancer activ-
ity (Schmidl et al., 2009).
Cellular DNA methylation processes are intimately
linked to histone modiﬁcations. DNA methyltransferases
partly interact with histone modifying enzymes
including histone deacetylates, suppressor of variegation
3–9 homologue 1 and enhancer of zeste homolog 2
(Fuks et al., 2000; Vire et al., 2006). Targeted
DNA methylation might depend upon preestablished
histone methylation (Johnson et al., 2002) or vice versa,
DNA methylation might constitute a cue by which his-
tone modiﬁcations are brought about. Here, we could
demonstrate that CTX astrocytes assembled more H4ac
at the CpG island and shore region of the GLT-1 gene
than CER astrocytes, whereas the repressive H3K27me3
mark at the shore region was slightly more abundant in
CER glia. Thus, this pattern of active and repressive
epigenetic marks at the shore region is in line with the
state of responsiveness of the GLT-1 gene to hormonal
factors. A concomitant presence of both active and re-
pressive chromatin at promoters was reported, for exam-
ple, for developmentally important genes in embryonic
stem cells (Bernstein et al., 2006). Assuming a similar
performance of the H4ac and H3K27me3 antibodies in
ChIP assays, the repressive H3K27me3 mark was much
less abundant at the GLT-1 promoter than H4ac, sug-
gesting that GLT-1 does not present a gene with biva-
lent chromatin structure.
The epigenetic signature of the shore region might not
only govern responsiveness to regulatory factors, but
might also itself be subject to changes subsequent to drug
exposure. Such reprogramming has already been
described (Murgatroyd et al., 2009). Rat embryonic neu-
ral stem cells undergo heritable changes paralleled by a
decrease in global DNA methylation when exposed to
DEX (Bose et al., 2010). In mice, chronic administration
of corticosterone for 4 weeks results in DNA demethyla-
tion of the FKBP5 gene in the hippocampus and hypo-
thalamus (Lee et al., 2010). In our study, the DEX-medi-
ated increase of GLT-1 expression was not associated
with a change of DNA methylation at the shore of the
GLT-1 promoter in CTX astrocytes. However, we observed
DEX-induced elevation of the levels of H4ac at the shore
in CTX, but not in CER astrocytes. Of note, epigenetic
plasticity of the shore region after HDAC-I exposure
reﬂected by a marked reduction of methylated CpG levels
was monitored in CTX astrocytes, as shown previously
(Perisic et al., 2010), but not in CER glia. These data
point to clear differences between these two brain regions
not only in the epigenetic signature of the shore region,
but also in its reprogramming after drug exposure.
Unexpectedly, VPA and TSA repressed basal GLT-1
mRNA expression in CER astrocytes, while in parallel a
prominent H4 hyperacetylation at the shore and the
CpG island was detected. On an unmethylated ectopic
reporter gene template, HDAC-I showed a clear stimula-
tory effect (Fig. 4). The presence of H3K27me3 at the
endogenous promoter might stabilize a hypermethylated
state of the DNA even under conditions of elevated H4ac
levels. Wong et al. recently demonstrated that
H3K27me3 marks are rather stable and connected to
DNA methylation recovery processes (Wong et al., 2011).
Adding another layer of complexity, HDAC-I might elicit
the synthesis of coregulatory factors that, depending on
the context of surrounding modiﬁcations, operate
differently on the endogenous and ectopic gene loci. In
addition, an important issue relates to the limitation of
plasmid-based reporter gene assays for assessing the
functional role of modiﬁed histone species, since the pro-
tein decoration of plasmid DNA is less multifarious as
compared with endogenous chromatin. However, re-
porter gene assays have been shown to be useful for the
focused investigation of regulatory activities of transact-
ing factors as well as cytosine methylation marks.
As demonstrated by Hassel et al., long-term treatment
of 3-month-old rats with VPA results in elevated levels
of hippocampal GLT-1 protein while CTX and CER
regions were not affected (Hassel et al., 2001). Moreover,
stimulatory effects of HDAC-I on GLT-1 protein levels in
primary CER astrocytes from neonatal rats have been
reported recently (Allritz et al., 2009). However, regula-
tion of protein levels may be completely uncoupled from
gene transcription and hence does not allow extrapolat-
ing for transcriptional outcome. Thus, studies suggest
that GLT-1 regulation by HDAC-I varies depending on
the brain region and developmental phase as well as on
the stage of gene expression.
In summary, our data add to the emerging concept that
CpG island shores, rather than CpG islands, are targets
of epigenetic (re)programming (see Fig. 7 for summary
and model) and important determinants of the spatiotem-
poral pattern of gene activity in health and disease (Doi
et al., 2009; Feber et al., 2011; Irizarry et al., 2009).
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